<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006082</article-id><article-id pub-id-type="pmc">PMC11859636</article-id><article-id pub-id-type="doi">10.3390/ph18020270</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00270</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reymova</surname><given-names>Farida</given-names></name><xref rid="af1-pharmaceuticals-18-00270" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4847-9711</contrib-id><name><surname>Sever</surname><given-names>Belgin</given-names></name><xref rid="af2-pharmaceuticals-18-00270" ref-type="aff">2</xref><xref rid="af3-pharmaceuticals-18-00270" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Topalan</surname><given-names>Edanur</given-names></name><xref rid="af4-pharmaceuticals-18-00270" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2210-5925</contrib-id><name><surname>Sevimli-Gur</surname><given-names>Canan</given-names></name><xref rid="af5-pharmaceuticals-18-00270" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1749-8293</contrib-id><name><surname>Can</surname><given-names>Mustafa</given-names></name><xref rid="af1-pharmaceuticals-18-00270" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5698-1109</contrib-id><name><surname>Tuyun</surname><given-names>Ama&#x000e7; Fatih</given-names></name><xref rid="af6-pharmaceuticals-18-00270" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4890-3124</contrib-id><name><surname>Ba&#x0015f;o&#x0011f;lu</surname><given-names>Faika</given-names></name><xref rid="af7-pharmaceuticals-18-00270" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3087-5145</contrib-id><name><surname>Ece</surname><given-names>Abdulilah</given-names></name><xref rid="af8-pharmaceuticals-18-00270" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Otsuka</surname><given-names>Masami</given-names></name><xref rid="af3-pharmaceuticals-18-00270" ref-type="aff">3</xref><xref rid="af9-pharmaceuticals-18-00270" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6705-4052</contrib-id><name><surname>Fujita</surname><given-names>Mikako</given-names></name><xref rid="af3-pharmaceuticals-18-00270" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9135-5397</contrib-id><name><surname>Demirci</surname><given-names>Hasan</given-names></name><xref rid="af4-pharmaceuticals-18-00270" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9796-7669</contrib-id><name><surname>Ciftci</surname><given-names>Halilibrahim</given-names></name><xref rid="af1-pharmaceuticals-18-00270" ref-type="aff">1</xref><xref rid="af3-pharmaceuticals-18-00270" ref-type="aff">3</xref><xref rid="af9-pharmaceuticals-18-00270" ref-type="aff">9</xref><xref rid="af10-pharmaceuticals-18-00270" ref-type="aff">10</xref><xref rid="c1-pharmaceuticals-18-00270" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Santos-Filho</surname><given-names>Osvaldo Andrade</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Ammazzalorso</surname><given-names>Alessandra</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00270"><label>1</label>Department of Bioengineering Sciences, Izmir Katip Celebi University, Izmir 35620, T&#x000fc;rkiye; <email>feridereymova@gmail.com</email> (F.R.); <email>mustafa.can@ikc.edu.tr</email> (M.C.)</aff><aff id="af2-pharmaceuticals-18-00270"><label>2</label>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, T&#x000fc;rkiye; <email>belginsever@anadolu.edu.tr</email></aff><aff id="af3-pharmaceuticals-18-00270"><label>3</label>Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan; <email>motsuka@gpo.kumamoto-u.ac.jp</email> (M.O.); <email>mfujita@kumamoto-u.ac.jp</email> (M.F.)</aff><aff id="af4-pharmaceuticals-18-00270"><label>4</label>Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, T&#x000fc;rkiye; <email>etopalan23@ku.edu.tr</email> (E.T.); <email>hdemirci@ku.edu.tr</email> (H.D.)</aff><aff id="af5-pharmaceuticals-18-00270"><label>5</label>Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir 35620, T&#x000fc;rkiye; <email>canansevimli@yahoo.com</email></aff><aff id="af6-pharmaceuticals-18-00270"><label>6</label>Department of Chemistry, Faculty of Science, Istanbul University, Fatih, Istanbul 34126, T&#x000fc;rkiye; <email>aftuyun@istanbul.edu.tr</email></aff><aff id="af7-pharmaceuticals-18-00270"><label>7</label>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, European University of Lefke, Northern Cyprus, TR-10, Mersin 99800, T&#x000fc;rkiye; <email>fabasoglu@eul.edu.tr</email></aff><aff id="af8-pharmaceuticals-18-00270"><label>8</label>Department of Medical Biochemistry, Faculty of Medicine, Biruni University, &#x00130;stanbul 34015, T&#x000fc;rkiye; <email>aece@biruni.edu.tr</email></aff><aff id="af9-pharmaceuticals-18-00270"><label>9</label>Department of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan</aff><aff id="af10-pharmaceuticals-18-00270"><label>10</label>Department of Molecular Biology and Genetics, Burdur Mehmet Akif Ersoy University, Istiklal Campus, Burdur 15030, T&#x000fc;rkiye</aff><author-notes><corresp id="c1-pharmaceuticals-18-00270"><label>*</label>Correspondence: <email>hciftci@mehmetakif.edu.tr</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>270</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>12</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Despite recent breakthroughs in cancer treatment, non-small cell lung cancer (NSCLC) and breast cancer remain major causes of death from all malignancies. The epidermal growth factor receptor (EGFR) is an important mediator of the pathways involved in cell proliferation, apoptosis, and angiogenesis. Thus, its overexpression triggers several types of cancer, including NSCLC and breast cancer. <bold>Methods:</bold> In the current study, we synthesized new pyrimidine-tethered compounds (chalcone derivative (<bold>B-4</bold>), pyrazoline&#x02013;carbothioamide (<bold>B-9</bold>), and pyrazoline&#x02013;thiazole hybrids (<bold>BH1-7</bold>)). These compounds were then tested for cytotoxicity against A549 NSCLC and MCF-7 breast cancer cells. <bold>Results:</bold> Of these, <bold>B-4</bold> displayed significant cytotoxicity against both cells (IC<sub>50</sub> = 6.70 &#x000b1; 1.02 &#x000b5;M for MCF-7; IC<sub>50</sub> = 20.49 &#x000b1; 2.7 &#x000b5;M for A549) compared to the standard agent lapatinib (IC<sub>50</sub> = 9.71 &#x000b1; 1.12 &#x000b5;M for MCF-7; IC<sub>50</sub> = 18.21 &#x000b1; 3.25 &#x000b5;M for A549). The anticancer potential of <bold>B-4</bold> between Jurkat leukemic T cells and peripheral blood mononuclear cells (PBMCs) (healthy) was found to be selective. Mechanistically, 11.9% and 10.2% of A549 and MCF-7 cells treated with <bold>B-4</bold>, respectively, underwent apoptosis and <bold>B-4</bold> produced 46% EGFR inhibition at a concentration of 10 &#x003bc;M. The <bold>B-4</bold>/EGFR complex obtained after induced fit docking was subjected to 300 ns of molecular dynamics simulation, which confirmed the stability of the complex in a mimicked biological environment. On the other hand, <bold>B-4</bold> was shown to have drug-like properties by in silico pharmacokinetic estimation. <bold>Conclusions:&#x000a0;B-4</bold> is an EGFR inhibitor and apoptosis inducer for future NSCLC and breast cancer studies.</p></abstract><kwd-group><kwd>pyrimidine</kwd><kwd>chalcone</kwd><kwd>pyrazoline</kwd><kwd>thiazole</kwd><kwd>lung cancer</kwd><kwd>breast cancer</kwd><kwd>apoptosis</kwd><kwd>EGFR</kwd><kwd>induced fit docking</kwd><kwd>molecular dynamics simulation</kwd></kwd-group><funding-group><award-group><funding-source>Scientific and Technological Research Council of Turkey (TUBITAK)</funding-source><award-id>122Z775</award-id></award-group><funding-statement>This study was supported by the Scientific and Technological Research Council of Turkey (TUBITAK) under the Grant Number 122Z775. The authors thank TUBITAK and the European Union for their support.<named-content content-type="graphic"><graphic xlink:href="pharmaceuticals-18-00270-i001.jpg" position="float"/></named-content></funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00270"><title>1. Introduction</title><p>Cancer is the second leading global killer after cardiovascular disorders and the leading cause of death in people under the age of 85. The coronavirus disease 2019 (COVID-19) pandemic affected the prognosis of cancer for a while, delaying diagnosis and treatment of cancer due to hospital-acquired infections, comorbidities, social and economic damage, limiting the use of health care settings, and health insurance [<xref rid="B1-pharmaceuticals-18-00270" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00270" ref-type="bibr">2</xref>]. The World Health Organisation&#x02019;s (WHO) cancer agency, the International Agency for Research on Cancer (IARC), has estimated the global burden of cancer. According to the report, lung cancer accounts for 2.5 million new cancer diagnoses, followed by female breast cancer at 2.3 million. Lung cancer is also the leading cause of cancer death with 1.8 million deaths, while breast cancer is responsible for 670,000 deaths, the highest number after lung, colorectal, and liver cancer types [<xref rid="B3-pharmaceuticals-18-00270" ref-type="bibr">3</xref>].</p><p>Tobacco use represents the most significant global risk factor for lung cancer [<xref rid="B4-pharmaceuticals-18-00270" ref-type="bibr">4</xref>], whereas environmental exposures, including the use of biomass fuels, arsenic, radon, industrial carcinogens, and air pollution, also exert a considerable influence on the incidence and mortality of lung cancer, with notable regional variations. The existence of disparate lung cancer subtypes and somatic mutations (e.g., epidermal growth factor receptor (EGFR) alterations) is indicative of geographic disparities in smoking patterns, environmental exposures, and genetics [<xref rid="B5-pharmaceuticals-18-00270" ref-type="bibr">5</xref>]. Furthermore, certain groups, including women, individuals infected with the human immunodeficiency virus (HIV), and never-smokers, exhibit distinctive characteristics [<xref rid="B6-pharmaceuticals-18-00270" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-18-00270" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-18-00270" ref-type="bibr">8</xref>]. Lung cancer is typically classified based on the origin of the cells and is broadly divided into non-small cell lung cancers (NSCLCs) and small cell lung cancers (SCLCs) [<xref rid="B9-pharmaceuticals-18-00270" ref-type="bibr">9</xref>]. NSCLC represents 80&#x02013;90% of all lung cancer cases, with approximately 50&#x02013;60% of patients being diagnosed at advanced or metastatic stages [<xref rid="B10-pharmaceuticals-18-00270" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-18-00270" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-18-00270" ref-type="bibr">12</xref>]. The survival rate for NSCLC remains low, with a 5-year survival rate of just 18% [<xref rid="B11-pharmaceuticals-18-00270" ref-type="bibr">11</xref>].</p><p>On the other hand, while breast cancer predominantly affects women, approximately 1% of cases occur in men [<xref rid="B13-pharmaceuticals-18-00270" ref-type="bibr">13</xref>]. Risk factors in developed countries include lifestyle changes, late childbirth, late-night work, and hormone replacement therapy, while in developing countries, high incidence and mortality are mainly due to lack of awareness, inadequate screening, delayed diagnosis, and limited medical resources [<xref rid="B14-pharmaceuticals-18-00270" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-18-00270" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-18-00270" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-18-00270" ref-type="bibr">17</xref>]. Breast cancer can be categorized in a number of ways, but the most widely used classification divides it into four molecular subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) [<xref rid="B18-pharmaceuticals-18-00270" ref-type="bibr">18</xref>]. Breast cancers that express no estrogen receptor (ER), progesterone receptor (PR), or HER2 are classified as TNBC. This category of breast cancer represents 10&#x02013;20% of all cases [<xref rid="B19-pharmaceuticals-18-00270" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-18-00270" ref-type="bibr">20</xref>].</p><p>The EGFR is a transmembrane receptor tyrosine kinase encoded by the EGFR gene, regulating essential cellular processes, including cell growth, metabolism, programmed cell death, and survival. The overexpression of the EGFR, gene amplification, and activating mutations are commonly observed in both NSCLC and certain subtypes of breast cancer. These genetic alterations contribute to tumor growth and resistance to therapy [<xref rid="B5-pharmaceuticals-18-00270" ref-type="bibr">5</xref>,<xref rid="B21-pharmaceuticals-18-00270" ref-type="bibr">21</xref>]. In NSCLC, this has established the EGFR tyrosine kinase (TK) as a critical target, prompting the development of various tyrosine kinase inhibitors (EGFR-TKIs) to suppress its abnormal activity [<xref rid="B22-pharmaceuticals-18-00270" ref-type="bibr">22</xref>]. At present, a number of EGFR-TKIs, including erlotinib, gefitinib, afatinib, and osimertinib, are available and are being actively employed in clinical practice to treat NSCLC, with a particular focus on targeting EGFR mutations [<xref rid="B23-pharmaceuticals-18-00270" ref-type="bibr">23</xref>]. Similarly, EGFR overexpression has been identified as a contributing factor in the development of HER2-positive and TNBC, where EGFR-targeted therapies, such as lapatinib and neratinib, have demonstrated considerable promise [<xref rid="B24-pharmaceuticals-18-00270" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-18-00270" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-18-00270" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-18-00270" ref-type="bibr">27</xref>]. Upon binding to ligands such as the epidermal growth factor (EGF), the EGFR forms homodimers or heterodimers with ErbB receptors, leading to the activation of its TK domains. This activation triggers autophosphorylation and initiates key signaling pathways, including the MAPK (RAS&#x02013;RAF&#x02013;MEK&#x02013;ERK) and PI3K&#x02013;AKT&#x02013;mTOR pathways [<xref rid="B28-pharmaceuticals-18-00270" ref-type="bibr">28</xref>]. These signaling pathways have been identified as promoting tumor growth, survival, and resistance to cell death, thereby providing further evidence to support the role of the EGFR as a critical driver of cancer progression [<xref rid="B29-pharmaceuticals-18-00270" ref-type="bibr">29</xref>]. EGFR-TKIs, such as erlotinib and gefitinib, work by competitively binding to the ATP-binding site of the EGFR TK domain, thereby preventing ATP from binding and disrupting the activation of the pathway [<xref rid="B30-pharmaceuticals-18-00270" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00270" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-18-00270" ref-type="bibr">32</xref>]. As a result, EGFR-TKIs have emerged as a key therapeutic strategy in both NSCLC and certain breast cancer subtypes.</p><p>Since pyrimidine nucleotides are known to be essential components in the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), pyrimidine-containing derivatives have been intensively investigated, especially for their potent antiproliferative effects [<xref rid="B33-pharmaceuticals-18-00270" ref-type="bibr">33</xref>]. So far, many pyrimidine-bearing analogs have been synthesized as EGFR inhibitors. Such inhibitors have been successfully designed to target different mutations in the TK domain of the EGFR and have been used in the treatment of cancers such as NSCLC. WZ40028 (<xref rid="pharmaceuticals-18-00270-f001" ref-type="fig">Figure 1</xref>) is the first pyrimidine-carrying compound belonging to the third class of EGFR inhibitors to show promising inhibitory activity against mutant EGFR<sup>T790M</sup>. Osimertinib (AZD9291) (<xref rid="pharmaceuticals-18-00270-f001" ref-type="fig">Figure 1</xref>) is the first pyrimidine-carrying drug active ingredient approved by the FDA, with very good clinical efficacy against NSCLC. In addition, rociletinib (CO1686) (<xref rid="pharmaceuticals-18-00270-f001" ref-type="fig">Figure 1</xref>) and olmutinib (HM61713) (<xref rid="pharmaceuticals-18-00270-f001" ref-type="fig">Figure 1</xref>) are other third class pyrimidine-based EGFR inhibitors. Due to the rapidly developing drug resistance that causes the long-term efficacy of these derivatives to decrease, studies for more effective pyrimidine-carrying EGFR inhibitors are ongoing [<xref rid="B34-pharmaceuticals-18-00270" ref-type="bibr">34</xref>]. Lapatinib (<xref rid="pharmaceuticals-18-00270-f001" ref-type="fig">Figure 1</xref>), which is used as a standard agent in this study, is a small molecule belonging to the 4-anilinoquinazoline class (a bicyclic heterocycle with benzene fused to pyrimidine) [<xref rid="B35-pharmaceuticals-18-00270" ref-type="bibr">35</xref>].</p><p>Chalcones are attracting considerable interest as potential anticancer candidates due to their relatively low side effects, high therapeutic index, and ease of synthesis. The 1,3-diphenyl-2-propen-1-one moiety can be easily modified to alter the biological potential of chalcones. Thus, chalcones have also been reported as having anticancer activity by inhibiting essential kinases such as the EGFR, vascular endothelial growth factor receptor-2 (VEGFR-2), and B-Raf (BRAF) kinase [<xref rid="B36-pharmaceuticals-18-00270" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-18-00270" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-18-00270" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-18-00270" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-18-00270" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-18-00270" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceuticals-18-00270" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00270" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-18-00270" ref-type="bibr">44</xref>]. Anti-NSCL or anti-breast cancer activity associated with EGFR inhibition has been demonstrated for some of the chalcone derivatives (<xref rid="pharmaceuticals-18-00270-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B45-pharmaceuticals-18-00270" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceuticals-18-00270" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-18-00270" ref-type="bibr">47</xref>].</p><p>Pyrazoline and thiazole are heterocyclic molecules with a wide range of biological profiles and a remarkable ability to influence the physico-chemical and biological properties of the compounds in which they are incorporated [<xref rid="B48-pharmaceuticals-18-00270" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceuticals-18-00270" ref-type="bibr">49</xref>]. To date, pyrazoline&#x02013;thiazole hybridization has been successfully used to design new conjugates with targeted anticancer activities, such as EGFR-directed activity against NSCLC and/or breast cancer (<xref rid="pharmaceuticals-18-00270-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B50-pharmaceuticals-18-00270" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceuticals-18-00270" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-18-00270" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceuticals-18-00270" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceuticals-18-00270" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>].</p><p>Based on the aforementioned data, in the current work, we synthesized new pyrimidine-based compounds (chalcone derivative (<bold>B-4</bold>), pyrazoline&#x02013;carbothioamide (<bold>B-9</bold>), and pyrazoline&#x02013;thiazole hybrids (<bold>BH1-7</bold>)). We then tested these compounds for their anticancer effects on A549 and MCF-7 cells, as well as their selective anticancer potential between Jurkat leukaemic T cells and peripheral blood mononuclear cells (PBMCs) (healthy). The most potent compound was further evaluated for its mechanistic anticancer effects, including inducing apoptosis in NSCLC and breast cancer cells and inhibiting the EGFR. Finally, for the most effective compound, molecular docking and molecular dynamic (MD) simulation were performed and several pharmacokinetic parameters were in silico anticipated.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00270"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-18-00270"><title>2.1. Chemistry</title><p>In the current work, initially, (<italic toggle="yes">E</italic>)-3-(2-(4-chlorophenyl)pyrimidin-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (<bold>B-4</bold>) was obtained via the Claisen Schmidt condensation of 1-(3,4-dimethoxyphenyl)ethan-1-one and 2-(4-chlorophenyl)pyrimidine-5-carbaldehyde under a basic condition. After that, 5-(2-(4-chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazole-1-carbothioamide (<bold>B-9</bold>) was synthesized as a result of the reaction of <bold>B-4</bold> and thiosemicarbazide in the presence of NaOH. Finally, new pyrazoline&#x02013;thiazole hybrids (<bold>BH1-7</bold>) were afforded through Hantzsch thiazole synthesis, the condensation of &#x003b1;-haloketones (2-bromo-1-arylethanones) and thioamides (<bold>B-9</bold>) (<xref rid="pharmaceuticals-18-00270-sch001" ref-type="fig">Scheme 1</xref>).</p><p>The structures of <bold>B-4</bold>, <bold>B-9</bold>, and <bold>BH1-7</bold> were confirmed by spectral data (<sup>1</sup>H nuclear magnetic resonance, NMR), <sup>13</sup>C NMR, and high-resolution mass spectra (HRMS). In the <sup>1</sup>H NMR spectra of <bold>B-4</bold>, the characteristic propenone protons appeared as a multiplet at 7.69&#x02013;7.74 ppm along with aromatic protons. In the <sup>13</sup>C NMR spectra, the C<sub>2</sub>, C<sub>3</sub>, and carbonyl carbons of the propenone moiety were detected at 124.16 ppm, 144.89 ppm, and 187.48 ppm, respectively (<xref rid="pharmaceuticals-18-00270-f004" ref-type="fig">Figure 4</xref>). The amine protons, which were observed as a singlet at 8.71 ppm, the characteristic H<sub>A</sub> and H<sub>X</sub> pyrazoline protons, resonating as doublets of doublets at 3.23 ppm (<italic toggle="yes">J<sub>AB</sub></italic> = 17.55 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 3.70 Hz) and 6.05 ppm (<italic toggle="yes">J<sub>AX</sub></italic> = 3.70 Hz, <italic toggle="yes">J<sub>BX</sub></italic> = 11.35 Hz), and the H<sub>B</sub> proton seen as a multiplet at 3.83&#x02013;3.92 ppm, confirmed the main chemical structure of <bold>B-9</bold>. In addition, the C<sub>3</sub>, C<sub>4</sub>, and C<sub>5</sub> carbons of pyrazoline appeared at 152.35 ppm, 42.44 ppm, and 59.23 ppm, respectively. The C=S carbon, which appeared at 176.05 ppm, was also important in confirming the chemical structure of <bold>B-9</bold> (<xref rid="pharmaceuticals-18-00270-f004" ref-type="fig">Figure 4</xref>). The condensation of the thiocarbamoyl of <bold>B-9</bold> to the thiazoles of <bold>BH1-7</bold> is evidenced by the appearance of the C<sub>2</sub>, C<sub>4</sub>, and C<sub>5</sub> thiazole carbons of <bold>BH1-7</bold> at 164.09&#x02013;165.42 ppm, 146.41&#x02013;151.17 ppm, and 103.50&#x02013;108.14 ppm, respectively. Moreover, the formation of <bold>BH1-7</bold> was enhanced by the presence of H<sub>A</sub>, H<sub>B</sub>, and H<sub>X</sub> protons and C<sub>3</sub>, C<sub>4</sub>, and C<sub>5</sub> carbons, corresponding to the pyrazoline pattern (<xref rid="pharmaceuticals-18-00270-f004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec2dot2-pharmaceuticals-18-00270"><title>2.2. Cytotoxicity</title><p>The new pyrazoline&#x02013;thiazole hybrids (<bold>BH1-7</bold>) and new intermediates <bold>B-4</bold> and <bold>B-9</bold> were evaluated for cytotoxic activity against the A549 and MCF-7 cell lines compared to lapatinib using the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) assay. The anticancer activity of <bold>BH1-7</bold>, <bold>B-4</bold>, and <bold>B-9</bold> against A549 and MCF-7 cells was initially screened in three replicates at a concentration of 100 &#x000b5;M (<xref rid="pharmaceuticals-18-00270-f005" ref-type="fig">Figure 5</xref>a,b). Intriguingly, only the chalcone derivative <bold>B-4</bold> was found to reduce cell viability by more than 50% at a concentration of 100 &#x000b5;M against both cells. <bold>B-4</bold> (70%) was followed by <bold>B-9</bold> and <bold>BH-5</bold> at this concentration with 43% and 37% anti-NSCLC activity, respectively (<xref rid="pharmaceuticals-18-00270-f005" ref-type="fig">Figure 5</xref>a). In addition, the anti-breast cancer activity of <bold>B-4</bold> (70%) was followed by that of <bold>BH-5</bold>, <bold>BH-4</bold>, and <bold>B-9</bold> with the values of 39%, 38%, and 33%, respectively (<xref rid="pharmaceuticals-18-00270-f005" ref-type="fig">Figure 5</xref>b).</p><p><bold>B-4</bold> was the only molecule with over 50% inhibition against both A549 and MCF-7 cells at 100 &#x000b5;M and was therefore tested at 5 doses (1, 3, 10, 30, and 100 &#x000b5;M) (three replicates at each concentration), and the IC<sub>50</sub> values were calculated (<xref rid="pharmaceuticals-18-00270-t001" ref-type="table">Table 1</xref>). Compared to its anti-NSCLC activity, the anti-breast cancer activity of <bold>B-4</bold> was found to be higher. <bold>B-4</bold> displayed more significant anticancer activity against the MCF-7 cell line with an IC<sub>50</sub> value of 6.70 &#x000b1; 1.02 &#x000b5;M compared to lapatinib (IC<sub>50</sub> = 9.71 &#x000b1; 1.12 &#x000b5;M), while the anti-NSCLC activity profile of <bold>B-4</bold> (IC<sub>50</sub> = 20.49 &#x000b1; 2.71 &#x000b5;M) was similar to that of lapatinib (IC<sub>50</sub> = 18.21 &#x000b1; 3.25 &#x000b5;M) (<xref rid="pharmaceuticals-18-00270-t001" ref-type="table">Table 1</xref>).</p><p>As shown in <xref rid="pharmaceuticals-18-00270-t001" ref-type="table">Table 1</xref>, the selectivity of the anticancer activity of <bold>B-4</bold> was also examined between Jurkat T cells and PBMCs (healthy). The SI value found by the ratio of the IC<sub>50</sub> value for Jurkat cells (1.50 &#x000b1; 0.40 &#x000b5;M) to the IC<sub>50</sub> value for PBMCs (68.89 &#x000b1; 10.28 &#x000b5;M) was 45.93 for <bold>B-4</bold> compared to lapatinib (SI = 8.89).</p></sec><sec id="sec2dot3-pharmaceuticals-18-00270"><title>2.3. Apoptosis</title><p>Since <bold>B-4</bold> was found to be the most effective and selective anticancer agent, the level of apoptosis in both A549 (<xref rid="pharmaceuticals-18-00270-f006" ref-type="fig">Figure 6</xref>a) and MCF-7 (<xref rid="pharmaceuticals-18-00270-f006" ref-type="fig">Figure 6</xref>b) cells was assessed by using the Annexin V/ethidium homodimer III staining technique, with green, yellow, and red staining indicating apoptotic, necrotic, or late apoptotic cells, respectively. This staining was observed by a fluorescence microscope. The findings showed that <bold>B-4</bold> induced apoptosis in 11.9% and 10.2% of A549 and MCF-7 cells, respectively.</p></sec><sec id="sec2dot4-pharmaceuticals-18-00270"><title>2.4. EGFR Inhibition</title><p>The EGFR is a key transmembrane protein in the occurrence and development of NSCLC and breast cancer. The strong anti-NSCLC and anti-breast cancer activity profile of <bold>B-4</bold> led us to investigate its ability to inhibit the EGFR. According to the results, <bold>B-4</bold> showed 46% EGFR inhibition at a concentration of 10 &#x003bc;M, with weak inhibition at a concentration of 1 &#x003bc;M (<xref rid="pharmaceuticals-18-00270-f007" ref-type="fig">Figure 7</xref>).</p></sec><sec id="sec2dot5-pharmaceuticals-18-00270"><title>2.5. Molecular Docking and MD Simulation</title><p>In order to evaluate the reliability of the molecular docking, as an internal validation [<xref rid="B56-pharmaceuticals-18-00270" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceuticals-18-00270" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-18-00270" ref-type="bibr">58</xref>], the native ligand in the X-ray crystal structure was first docked into the active pocket of the EGFR. The root mean square deviation (RMSD) between the resulting and the X-ray conformations was calculated as 0.97 &#x000c5;. The 3D superimposed conformations of the native ligand and the docked pose are given in <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref> (<xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figure S1</xref>).</p><p>In general, molecular docking may not give reliable results as it does not consider a biological environment. Hence, we consulted MD simulations in which we put the <bold>B-4</bold>/EGFR docked pose in a sample of water and salt concentration and simulated it for 300 ns. Several metrics were calculated at the end of the simulation to evaluate the results. As can be clearly seen from <xref rid="pharmaceuticals-18-00270-f008" ref-type="fig">Figure 8</xref>, the protein&#x02013;ligand complex is quite stable during the whole simulation period. The RMSD of the protein reaches equilibrium after just ~10 ns and stays lower than 3 &#x000c5; with very small variations. Besides staying in the binding site, the very low RMSD value of the ligand shows that compound <bold>B-4</bold> almost did not change its overall position.</p><p>The frequencies of the ligand contacts during 300 ns of the simulation were calculated (<xref rid="pharmaceuticals-18-00270-f009" ref-type="fig">Figure 9</xref>) as well. During more than 95% of the entire simulation, a hydrogen bond between the carbonyl oxygen of <bold>B-4</bold> and the amino acid residue MET793 was observed. A &#x003c0;-&#x003c0; interaction between the 1,2-dimethoxybenzene ring of <bold>B-4</bold> and PHE997 was also observed for more than half of the MD simulation. The nitrogen atom in the pyrimidine ring and methoxy oxygens of <bold>B-4</bold> act as a hydrogen bond acceptor and engage in strong hydrogen bond interactions with the waters in the EGFR binding site.</p><p>We also carried out <italic toggle="yes">k</italic>-Means cluster analysis to group together all frames of the MD trajectories having similar protein conformations. Out of 10 generated clusters, we selected the most populated cluster, which contains the highest fraction of the overall frames. The 2D interaction map of <bold>B-4</bold>/EGFR is depicted in <xref rid="pharmaceuticals-18-00270-f010" ref-type="fig">Figure 10</xref>. Notably, the 2D interaction map of the selected cluster is in well agreement with the frequency of the ligand contacts.</p></sec><sec id="sec2dot6-pharmaceuticals-18-00270"><title>2.6. In Silico Pharmacokinetic Estimation</title><p><bold>B-4</bold> was subjected to in silico profiling for various absorption, distribution, metabolism, and excretion (ADME) parameters such as the coefficients of octanol/water partition (QPlogPo/w), aqueous solubility (QPlogS), and human serum albumin binding (QPlogKhsa). The compatibility of <bold>B-4</bold> with Lipinski&#x02019;s rule of 5 and Jorgensen&#x02019;s rule of 3 was also determined using the QikProp module [<xref rid="B59-pharmaceuticals-18-00270" ref-type="bibr">59</xref>]. In addition, the in silico inhibition potential of <bold>B-4</bold> on various cytochrome P450 (CYP) enzymes including CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4, together with the assessment of blood&#x02013;brain barrier (BBB) permeability, was implemented using the SwissADME web service [<xref rid="B60-pharmaceuticals-18-00270" ref-type="bibr">60</xref>].</p><p><bold>B-4</bold> demonstrated a pronounced pharmacokinetic profile in which all metrics were within the appropriate intervals, as follows: QPlogPo/w, QPlogS, and QPlogKhsa were calculated with values of 4.451, &#x02212;5.634, and 0.371, respectively, within the ranges (&#x02212;2 to 6.5, &#x02212;6.5 to 0.5, and &#x02212;1.5 to 1.5, respectively). On a scale of 0&#x02013;100% (&#x0003e;80% is high; &#x0003c;25% is low), <bold>B-4</bold> also displayed impressive oral absorption (100%) in humans. The parameters of Lipinski&#x02019;s rule of 5 and Jorgensen&#x02019;s rule of 3 were also fulfilled by <bold>B-4</bold>.</p><p>The values for oral bioavailability, including saturation (INSATU), size (SIZE), polarity (POLAR), solubility (INSOLU), lipophilicity (LIPO), and flexibility (FLEX), were shown in the pink area of the radar (<xref rid="pharmaceuticals-18-00270-f011" ref-type="fig">Figure 11</xref>). <bold>B-4</bold> was found only outside the INSATU, while for the other values, it was in the pink area. <bold>B-4</bold> was associated with the inhibition of CYP1A2, CYP2C19, CYP2C9, and CYP3A4, but not CYP2D6. This suggests that <bold>B-4</bold> may cause potential drug&#x02013;drug interactions.</p><p>The BOILED egg model (<xref rid="pharmaceuticals-18-00270-f012" ref-type="fig">Figure 12</xref>) describes whether a molecule has properties for the passive gastrointestinal absorption and penetration of the blood&#x02013;brain barrier (BBB). The results showed that <bold>B-4</bold> was predicted to penetrate the brain (shown in yellow) and not act as a substrate for P-glycoprotein (red dot), reducing the possibility of its resistance to cancer cell lines by efflux.</p></sec></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-18-00270"><title>3. Discussion</title><p>In the current work, we designed and synthesized new pyrimidine-based compounds (chalcone derivative (<bold>B-4</bold>), pyrazoline&#x02013;carbothioamide (<bold>B-9</bold>), and pyrazoline&#x02013;thiazole hybrids (<bold>BH1-7</bold>). We then evaluated the anticancer effects of these compounds against A549 NSCLC and MCF-7 breast cancer cells by MTT assay and, more mechanistically, the apoptotic effects in A549 and MCF-7 cells and the EGFR inhibitory potential of the most effective compound. In silico studies were also performed to determine the binding potential to the ATP binding site of the EGFR and key pharmacokinetic determinants of the most potent compound.</p><p>WZ40028, osimertinib, rociletinib (CO1686), and olmutinib (HM61713) are well-known pyrimidine-based EGFR inhibitors. In addition, the quinazoline ring, which is a fused bicyclic heterocycle with benzene and pyrimidine, is found in most EGFR inhibitors, such as lapatinib (<xref rid="pharmaceuticals-18-00270-f001" ref-type="fig">Figure 1</xref>). Meanwhile, chalcone derivatives have been delved into for their potential EGFR-directed activities against NSCLC and/or breast cancer. Alshwah et al., 2017 [<xref rid="B45-pharmaceuticals-18-00270" ref-type="bibr">45</xref>] have reported the triazoloquinoxaline&#x02013;chalcone derivatives for their EGFR-related anticancer effects, including anti-breast cancer activity. Compound <bold>7e</bold> (<xref rid="pharmaceuticals-18-00270-f002" ref-type="fig">Figure 2</xref>) revealed anticancer activity against MCF-7 cells with an IC<sub>50</sub> value of 8.23 &#x000b1; 0.25 &#x003bc;M and EGFR inhibition (IC<sub>50</sub> = 0.083 &#x000b1; 0.04 &#x003bc;M). In another study, among xanthine/chalcone hybrids, compound <bold>11</bold> (<xref rid="pharmaceuticals-18-00270-f002" ref-type="fig">Figure 2</xref>) showed cytotoxicity against A549 and MCF-7 cells with IC<sub>50</sub> values of 1.8 &#x000b1; 0.7 &#x003bc;M and 1.3 &#x000b1; 0.9 &#x003bc;M, respectively. Compound <bold>11</bold> also inhibited the EGFR with an IC<sub>50</sub> value of 0.3 &#x003bc;M [<xref rid="B46-pharmaceuticals-18-00270" ref-type="bibr">46</xref>]. Quinoline/chalcone hybrids with 1,2,4-triazole moiety were examined for EGFR-directed anti-NSCLC and anti-breast cancer activity. Compound <bold>7b</bold> (<xref rid="pharmaceuticals-18-00270-f002" ref-type="fig">Figure 2</xref>) exhibited anticancer effects on A549 and MCF-7 cells with IC<sub>50</sub> values of 3.6 &#x000b1; 0.05 &#x003bc;M and 3.3 &#x000b1; 0.08 &#x003bc;M, respectively. The EGFR inhibitory effect of compound <bold>7b</bold> was found as 1.3 &#x000b1; 1.2 &#x003bc;M [<xref rid="B47-pharmaceuticals-18-00270" ref-type="bibr">47</xref>]. All these studies indicated that the anti-NSCLC and anti-breast cancer potential of chalcones was boosted by the combination of chalcones with various heterocycles bearing multiple azoles.</p><p>With regard to the studies involving the anti-NSCLC and anti-breast cancer activity of thiazolyl&#x02013;pyrazoline hybrids associated with EGFR inhibition, there are promising results. Lv et al., 2011 [<xref rid="B50-pharmaceuticals-18-00270" ref-type="bibr">50</xref>] and George et al., 2019 [<xref rid="B51-pharmaceuticals-18-00270" ref-type="bibr">51</xref>] observed that compounds <bold>11</bold> (<xref rid="pharmaceuticals-18-00270-f003" ref-type="fig">Figure 3</xref>) and <bold>6c</bold> (<xref rid="pharmaceuticals-18-00270-f003" ref-type="fig">Figure 3</xref>) showed remarkable anticancer activity against the MCF-7 cell line with IC<sub>50</sub> values of 0.07 &#x003bc;M and 0.227 &#x003bc;M, respectively. Compounds <bold>11</bold> and <bold>6c</bold> also inhibited the EGFR with IC<sub>50</sub> values of 0.06 &#x003bc;M and 31.80 nM, respectively. In another study, we demonstrated that compound <bold>3f</bold> (<xref rid="pharmaceuticals-18-00270-f003" ref-type="fig">Figure 3</xref>) was cytotoxic against both A549 NSCLC and MCF-7 cells with IC<sub>50</sub> values of 10.76 &#x003bc;M and 8.05 &#x003bc;M, respectively. Compound <bold>3f</bold> was also able to inhibit the EGFR with an IC<sub>50</sub> value of 4.34 &#x003bc;M [<xref rid="B52-pharmaceuticals-18-00270" ref-type="bibr">52</xref>]. Abdelsalam et al., 2022 [<xref rid="B53-pharmaceuticals-18-00270" ref-type="bibr">53</xref>] identified two compounds (compounds <bold>3b</bold> and <bold>3d</bold>) (<xref rid="pharmaceuticals-18-00270-f003" ref-type="fig">Figure 3</xref>) in this series showing notable anti-NSCLC activity, inhibiting EGFR at nanomolar levels. On the other hand, Fakhry et al., 2022 [<xref rid="B54-pharmaceuticals-18-00270" ref-type="bibr">54</xref>] demonstrated that compound <bold>6e</bold> (<xref rid="pharmaceuticals-18-00270-f003" ref-type="fig">Figure 3</xref>) revealed cytotoxicity towards MCF-7 cells and EGFR inhibitory activity with IC<sub>50</sub> values of 7.21 &#x003bc;M and 0.009 &#x000b5;M, respectively. In our other study [<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>], compound <bold>BTT-5</bold> (<xref rid="pharmaceuticals-18-00270-f003" ref-type="fig">Figure 3</xref>) was determined to possess anti-NSCLC (IC<sub>50</sub> = 9.51 &#x003bc;M) activity and selective EGFR inhibitory (58.32%) effects at a 10 &#x000b5;M concentration. As shown in these studies, the methoxy and halogen substitutions on the phenyl ring had a positive effect on the anticancer activity of pyrazoline&#x02013;thiazole hybrids.</p><p>In our current study, the chalcone derivative <bold>B-4</bold> was found to be the most effective cytotoxic and apoptotic agent against both A549 and MCF-7 cells. This indicates that the propenone (<bold>B-4</bold>) moiety improved the anticancer activity compared to pyrazoline&#x02013;carbothioamide (<bold>B-9</bold>) and pyrazoline&#x02013;thiazole (<bold>BH1-7</bold>) scaffolds. Among <bold>BH1-7</bold>, the 4-bromophenyl substitution increased the anti-NSCLC and anti-breast cancer activity, as shown in <bold>BH-5</bold>. This result is also consistent with our previous findings, as shown in <bold>BTT-5</bold> [<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>].</p><p><bold>B-4</bold> also exhibited cytotoxic effects against Jurkat cells, showing less cytotoxicity against PBMCs (healthy). The SI value, which was calculated between the IC<sub>50</sub> values of the PBMCs and the Jurkat cells, indicates a high degree of selectivity of <bold>B-4</bold>. The high anticancer activity of <bold>B-4</bold> against Jurkat cells also suggested that <bold>B-4</bold> might act on other kinases in addition to the EGFR.</p><p><bold>B-4</bold>-treated A549 and MCF-7 cells underwent significant apoptosis after 24 h. In addition, <bold>B-4</bold> significantly inhibited the EGFR at a concentration of 10 &#x000b5;M. Molecular docking studies supported the importance of the propenone moiety for key hydrogen bonding in the ATP binding site of the EGFR.</p><p>The ADME analysis put emphasis on <bold>B-4&#x02032;</bold>s drug-like properties of optimal lipophilicity, water solubility, and binding to human serum albumin, which might influence the volume of distribution and half-life of <bold>B-4</bold>. One of the main sites of metastasis in NSCLC is the brain. The ability of drugs to cross the BBB is therefore very important. <bold>B-4</bold> has been shown to be capable of BBB penetration. <bold>B-4</bold> has the potential to be metabolized by the CYP enzymes tested, with the exception of CYP2D6, resulting in possible drug&#x02013;drug interactions.</p></sec><sec id="sec4-pharmaceuticals-18-00270"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-18-00270"><title>4.1. Chemistry</title><p>All reagents have been purchased and used commercially and have not been purified, unless otherwise stated. The melting point (M.p.) of each compound was determined using an MP90 digital melting point apparatus (Mettler Toledo, Columbus, OH, USA) and was not corrected. Thin layer chromatography (TLC) was performed on silica gel 60 F254 aluminum sheets (Merck, Darmstadt, Germany). A Bruker NMR spectrometer (Bruker, Billerica, MA, USA) was used for <sup>1</sup>H nuclear magnetic resonance (NMR) and <sup>13</sup>C NMR spectra, while a JEOL JMS-700 Station/JMS-BU-20-GCmate (JEOL, Akishima, Tokyo) was used for high-resolution mass spectra (HRMS).</p><sec id="sec4dot1dot1-pharmaceuticals-18-00270"><title>4.1.1. Synthesis of (E)-3-(2-(4-Chlorophenyl)pyrimidin-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (<bold>B-4</bold>)</title><p>Yield: 82%. M.p. 189.6 &#x000b0;C</p><p>2-(4-Chlorophenyl)pyrimidine-5-carbaldehyde (1 mmol) was added to 1-(3,4-dimethoxyphenyl)ethan-1-one (1 mmol) and NaOH (1.1 mmol) in ethanol. The final mixture was stirred for 24 h under room temperature (r.t.) conditions. After TLC control, the mixture was transferred to crushed ice. Precipitation was filtered, waterwashed, and dried. The final product was crystalized from ethanol [<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>].</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.98 (6H, s, OCH<sub>3</sub>), 6.96 (1H, d, <italic toggle="yes">J</italic> = 10.90 Hz, aromatic), 7.48 (2H, d, <italic toggle="yes">J</italic> = 10.80 Hz, aromatic), 7.64 (1H, s, aromatic), 7.69&#x02013;7.74 (3H, m, C<sub>2</sub>-H, C<sub>3</sub>-H ve aromatic), 8.44 (2H, d, <italic toggle="yes">J</italic> = 8.35 Hz, aromatic), 9.02 (2H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 56.05 (2CH<sub>3</sub>, OCH<sub>3</sub>), 109.99 (CH, aromatic), 110.87 (CH, aromatic), 123.34 (CH, aromatic), 124.16 (CH, C<sub>2</sub>-H), 129.10 (2CH, aromatic), 130.00 (2CH, aromatic), 130.58 (C, aromatic), 135.51 (C, aromatic), 136.50 (C, aromatic), 138.01 (C, aromatic), 144.89 (CH, C<sub>3</sub>-H), 149.65 (C, aromatic), 154.01 (C, aromatic), 156.48 (2CH, aromatic), 164.21 (C, aromatic), 187.48 (C, C=O). HRMS (FAB) calcd. for C<sub>21</sub>H<sub>18</sub>O<sub>3</sub>N<sub>2</sub>Cl [M+H]<sup>+</sup>: m/z = 381.1006; found: 381.0992. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S2&#x02013;S4</xref>).</p></sec><sec id="sec4dot1dot2-pharmaceuticals-18-00270"><title>4.1.2. Synthesis of 5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (<bold>B-9</bold>)</title><p>Yield: 76%. M.p. 200.3 &#x000b0;C</p><p>The mixture of <bold>B-4</bold> (3 mmol), thiosemicarbazide (4.5 mmol), and sodium hydroxide (3 mmol) in ethanol was allowed to reflux for 8&#x02013;12 h. The solution was placed in crushed ice and cooled before washing with water. Precipitation was filtered, waterwashed, and dried. The final product was crystalized from ethanol [<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>].</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.23 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.55 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 3.70 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.83&#x02013;3.92 (1H, m, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 3.92 (3H, s, OCH<sub>3</sub>), 3.93 (3H, s, OCH<sub>3</sub>), 6.05 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 11.35 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 3.70 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 6.86 (1H, d, <italic toggle="yes">J</italic> = 9.10 Hz, aromatic), 7.12 (1H, d, <italic toggle="yes">J</italic> = 10.00 Hz, aromatic), 7.35&#x02013;7.43 (3H, m, aromatic), 8.32 (2H, d, <italic toggle="yes">J</italic> = 7.55 Hz, aromatic), 8.71 (2H, s, NH<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.44 (CH<sub>2</sub>, C<sub>4</sub> pyrazoline), 56.10 (2CH<sub>3</sub>, OCH<sub>3</sub>), 59.23 (CH, C<sub>5</sub> pyrazoline), 108.54 (CH, aromatic), 110.89 (CH, aromatic), 121.47 (CH, aromatic), 122.72 (C, aromatic), 128.85 (2CH, aromatic), 129.56 (2CH, aromatic), 132.96 (C, aromatic), 135.44 (C, aromatic), 136.87 (C, aromatic), 137.87 (C, aromatic), 149.48 (C, aromatic), 152.35 (C, C<sub>3</sub> pyrazoline), 155.48 (2CH, aromatic), 162.99 (C, aromatic), 176.05 (C, C=S). HRMS (FAB) calcd. for C<sub>22</sub>H<sub>21</sub>O<sub>2</sub>N<sub>5</sub>ClS [M+H]<sup>+</sup>: m/z = 454.1104; found: 454.1113. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S5&#x02013;S7</xref>).</p></sec><sec id="sec4dot1dot3-pharmaceuticals-18-00270"><title>4.1.3. Synthesis of 2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(aryl)thiazoles (<bold>BH1-7</bold>)</title><p><bold>B-9</bold> (0.8 mmol) and 2-bromo-1-arylethanone (0.8 mmol) were refluxed in ethanol for 2&#x02013;6 h. Precipitation was filtered, waterwashed, and dried. The final product was crystalized from ethanol [<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>].</p><p>2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazol-1-yl)-4-(phenyl)thiazole (<bold>BH-1</bold>)</p><p>Yield: 75%. M.p. 217.3 &#x000b0;C</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.35 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.15 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.25 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.92 (3H, s, OCH<sub>3</sub>), 3.90&#x02013;3.95 (1H, m, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 3.98 (3H, s, OCH<sub>3</sub>), 5.65 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 11.90 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.25 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 6.85 (1H, s, aromatic), 6.88 (1H, d, <italic toggle="yes">J</italic> = 8.85 Hz, aromatic), 7.12 (1H, d, <italic toggle="yes">J</italic> = 8.25 Hz, aromatic), 7.22 (1H, d, <italic toggle="yes">J</italic> = 7.35 Hz, aromatic), 7.31 (2H, d, <italic toggle="yes">J</italic> = 7.95 Hz, aromatic), 7.42 (3H, d, <italic toggle="yes">J</italic> = 8.88 Hz, aromatic), 7.47 (1H, s, aromatic), 7.65&#x02013;7.68 (2H, m), 8.36 (2H, d, <italic toggle="yes">J</italic> = 8.70 Hz, aromatic), 8.89 (1H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.52 (CH<sub>2</sub>, pyrazoline C<sub>4</sub>), 56.00 (CH<sub>3</sub>, OCH<sub>3</sub>), 56.14 (CH<sub>3</sub>, OCH<sub>3</sub>), 60.95 (CH, pyrazoline C<sub>5</sub>), 103.97 (CH, thiazole C<sub>5</sub>), 108.45 (CH, aromatic), 111.11 (CH, aromatic), 120.37 (CH, aromatic), 123.74 (C, aromatic), 125.84 (2CH, aromatic), 127.68 (CH, aromatic), 128.58 (2CH, aromatic), 128.90 (2CH, aromatic), 129.54 (2CH, aromatic), 132.56 (C, aromatic), 134.63 (C, aromatic), 135.90 (C, aromatic), 137.05 (C, aromatic), 149.34 (C, aromatic), 151.17 (C, thiazole C<sub>4</sub>), 151.60 (C, aromatic), 151.84 (C, pyrazoline C<sub>3</sub>), 156.29 (2CH, aromatic), 163.13 (C, aromatic), 165.08 (C, thiazole C<sub>2</sub>). HRMS (FAB) calcd. for C<sub>30</sub>H<sub>25</sub>O<sub>2</sub>N<sub>5</sub>ClS [M+H]<sup>+</sup>: m/z = 554.1417; found: 554.1403. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S8&#x02013;S10</xref>).</p><p>2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazol-1-yl)-4-(4-(nitro)phenyl)thiazole (<bold>BH-2</bold>)</p><p>Yield: 71%. M.p. 208.8 &#x000b0;C</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.42 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.75 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.60 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.95 (3H, s, OCH<sub>3</sub>), 4.00 (3H, s, OCH<sub>3</sub>), 4.02&#x02013;4.05 (1H, m, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 5.68 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 12.10 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.10 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 6.91 (1H, d, <italic toggle="yes">J</italic> = 8.10 Hz, aromatic), 7.08 (1H, s, aromatic), 7.17 (1H, d, <italic toggle="yes">J</italic> = 10.00 Hz, aromatic), 7.45 (2H, d, <italic toggle="yes">J</italic> = 8.60 Hz, aromatic), 7.49 (1H, s), 7.80 (2H, d, <italic toggle="yes">J</italic> = 8.80 Hz, aromatic), 8.19 (2H, d, <italic toggle="yes">J</italic> = 9.85 Hz, aromatic), 8.39 (2H, d, <italic toggle="yes">J</italic> = 9.85 Hz, aromatic), 8.90 (2H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.99 (CH<sub>2</sub>, pyrazoline C<sub>4</sub>), 55.78 (2CH<sub>3</sub>, OCH<sub>3</sub>), 60.39 (CH, pyrazoline C<sub>5</sub>), 108.14 (CH, thiazole C<sub>5</sub>), 114.24 (2CH, aromatic), 123.26 (CH, aromatic), 124.18 (C, aromatic), 126.27 (2CH, aromatic), 128.25 (2CH, aromatic), 128.93 (2CH, aromatic), 129.71 (2CH, aromatic), 132.32 (C, aromatic), 135.71 (C, aromatic), 137.27 (C, aromatic), 140.61 (C, aromatic), 146.86 (C, aromatic), 149.57 (C, thiazole C<sub>4</sub>), 152.28 (C, aromatic), 156.40 (2CH, aromatic), 160.31 (C, pyrazoline C<sub>3</sub>), 161.56 (C, aromatic), 163.24 (C, aromatic), 165.42 (C, thiazole C<sub>2</sub>). HRMS (FAB) calcd. for C<sub>30</sub>H<sub>24</sub>O<sub>4</sub>N<sub>6</sub>ClS [M+H]<sup>+</sup>: m/z = 599.1268; found: 599.1232. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S11&#x02013;S13</xref>).</p><p>2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazol-1-yl)-4-(4-(fluoro)phenyl)thiazole (<bold>BH-3</bold>)</p><p>Yield: 72%. M.p. 211.6 &#x000b0;C</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.36 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.35 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.10 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.93 (3H, s, OCH<sub>3</sub>), 3.95&#x02013;3.97 (1H, m, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 3.99 (3H, s, OCH<sub>3</sub>), 5.65 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 11.95 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.05 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 6.77 (1H, s, aromatic), 6.88 (1H, d, <italic toggle="yes">J</italic> = 7.65 Hz, aromatic), 6.99 (2H, t, <italic toggle="yes">J</italic> = 9.55 Hz, aromatic), 7.13 (1H, d, <italic toggle="yes">J</italic> = 8.55 Hz, aromatic), 7.43 (2H, d, <italic toggle="yes">J</italic> = 8.10 Hz, aromatic), 7.47 (1H, s, aromatic), 7.60&#x02013;7.63 (2H, m, aromatic), 8.37 (2H, d, <italic toggle="yes">J</italic> = 9.05 Hz, aromatic), 8.88 (2H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.60 (CH<sub>2</sub>, pyrazoline C<sub>4</sub>), 56.07 (2CH<sub>3</sub>, OCH<sub>3</sub>), 60.49 (CH, pyrazoline C<sub>5</sub>), 103.50 (CH, thiazole C<sub>5</sub>), 108.72 (C, aromatic), 111.53 (2CH, aromatic), 115.55 (C, aromatic), 120.32 (CH, aromatic), 123.73 (CH, aromatic), 127.62 (CH, aromatic), 128.89 (3CH, aromatic), 129.63 (3CH, aromatic), 132.52 (C, aromatic), 135.75 (C, aromatic), 137.24 (C, aromatic), 149.49 (C, aromatic), 150.62 (C, thiazole C<sub>4</sub>), 151.24 (C, aromatic), 151.98 (C, pyrazoline C<sub>3</sub>), 156.18 (2CH, aromatic), 158.10 (C, aromatic), 163.31 (C, aromatic), 165.15 (C, thiazole C<sub>2</sub>). HRMS (FAB) calcd. for C<sub>30</sub>H<sub>23</sub>O<sub>2</sub>N<sub>5</sub>ClFS [M+H]<sup>+</sup>: m/z = 572.1323; found: 571.1243. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S14&#x02013;S16</xref>).</p><p>2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazol-1-yl)-4-(4-(chloro)phenyl)thiazole (<bold>BH-4</bold>)</p><p>Yield: 80%. M.p. 187.8 &#x000b0;C</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.66 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.65 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.80 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.83 (3H, s, OCH<sub>3</sub>), 3.85 (3H, s, OCH<sub>3</sub>), 4.09 (1H, dd, <italic toggle="yes">J<sub>BA</sub></italic> = 17.65 Hz, <italic toggle="yes">J<sub>BX</sub> =</italic> 11.70, Hz, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 5.75 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 11.70 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.85 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 7.07 (1H, d, <italic toggle="yes">J</italic> = 8.30 Hz, aromatic), 7.33 (2H, t, <italic toggle="yes">J</italic> = 8.15 Hz, aromatic), 7.40 (3H, d, <italic toggle="yes">J</italic> = 8.70 Hz, aromatic), 7.43 (1H, s, aromatic), 7.58 (2H, d, <italic toggle="yes">J</italic> = 8.85 Hz, aromatic), 7.72 (2H, d, <italic toggle="yes">J</italic> = 8.50 Hz, aromatic), 8.38 (2H, d, <italic toggle="yes">J</italic> = 8.55 Hz, aromatic), 9.03 (2H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.92 (CH<sub>2</sub>, pyrazoline C<sub>4</sub>), 55.95 (2CH<sub>3</sub>, OCH<sub>3</sub>), 60.70 (CH, pyrazoline C<sub>5</sub>), 104.24 (CH, thiazole C<sub>5</sub>), 108.53 (CH, aromatic), 110.98 (CH, aromatic), 120.18 (C, aromatic), 123.86 (CH, aromatic), 127.12 (2CH, aromatic), 128.71 (2CH, aromatic), 128.84 (2CH, aromatic), 129.59 (2CH, aromatic), 132.38 (C, aromatic), 133.20 (C, aromatic), 133.78 (C, aromatic), 135.72 (C, aromatic), 137.11 (C, aromatic), 149.40 (C, thiazole C<sub>4</sub>), 150.52 (C, pyrazoline C<sub>3</sub>), 151.28 (C, aromatic), 151.92 (C, aromatic), 156.19 (2CH, aromatic), 163.37 (C, aromatic), 165.06 (C, thiazole C<sub>2</sub>). HRMS (FAB) calcd. for C<sub>30</sub>H<sub>24</sub>O<sub>2</sub>N<sub>5</sub>Cl<sub>2</sub>S [M+H]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> = 588.1028; found: 587.0917. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S17&#x02013;S19</xref>).</p><p>2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazol-1-yl)-4-(4-(bromo)phenyl)thiazole (<bold>BH-5</bold>)</p><p>Yield: 83%. M.p. 189.7 &#x000b0;C</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.38 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.35 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.15 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.94 (3H, s, OCH<sub>3</sub>), 3.99 (3H, s, OCH<sub>3</sub>), 3.99&#x02013;4.04 (1H, m, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 5.66 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 11.90 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.25 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 6.86 (1H, s, aromatic), 6.90 (1H, d, <italic toggle="yes">J</italic> = 8.40 Hz, aromatic), 7.15 (1H, d, <italic toggle="yes">J</italic> = 8.05 Hz, aromatic), 7.43&#x02013;7.45 (4H, m, aromatic), 7.48 (1H, s, aromatic), 7.53 (2H, d, <italic toggle="yes">J</italic> = 8.75 Hz, aromatic), 8.38 (2H, d, <italic toggle="yes">J</italic> = 8.65 Hz, aromatic), 8.89 (2H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.68 (CH<sub>2</sub>, pyrazoline C<sub>4</sub>), 56.04 (2CH<sub>3</sub>, OCH<sub>3</sub>), 60.95 (CH, pyrazoline C<sub>5</sub>), 104.36 (CH, thiazole C<sub>5</sub>), 108.65 (CH, aromatic), 110.98 (CH, aromatic), 120.30 (CH, aromatic), 121.53 (C, aromatic), 123.61 (C, aromatic), 127.29 (2CH, aromatic), 128.89 (2CH, aromatic), 129.74 (2CH, aromatic), 131.95 (2CH, aromatic), 132.33 (C, aromatic), 133.55 (C, aromatic), 135.63 (C, aromatic), 137.35 (C, aromatic), 149.40 (C, aromatic), 150.49 (C, thiazole C<sub>4</sub>), 151.25 (C, pyrazoline C<sub>3</sub>), 152.05 (C, aromatic), 156.21 (2CH, aromatic), 157.58 (C, aromatic), 165.20 (C, thiazole C<sub>2</sub>). HRMS (FAB) calcd. for C<sub>30</sub>H<sub>24</sub>O<sub>2</sub>N<sub>5</sub>ClBrS [M+H]<sup>+</sup>: m/z = 632.0523; found: 632.0474. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S20&#x02013;S22</xref>).</p><p>2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazol-1-yl)-4-(4-(cyano)phenyl)thiazole (<bold>BH-6</bold>)</p><p>Yield: 82%. M.p. 205.5 &#x000b0;C</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.40 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.40 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.25 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.95 (3H, s, OCH<sub>3</sub>), 3.99 (3H, s, OCH<sub>3</sub>), 4.01&#x02013;4.04 (1H, m, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 5.67 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 12.40 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.55 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 6.91 (1H, d, <italic toggle="yes">J</italic> = 8.10 Hz, aromatic), 7.01 (1H, s, aromatic), 7.16 (1H, d, <italic toggle="yes">J</italic> = 8.40 Hz, aromatic), 7.45 (2H, d, <italic toggle="yes">J</italic> = 9.05 Hz, aromatic), 7.48 (1H, s, aromatic), 7.60 (2H, d, <italic toggle="yes">J</italic> = 8.60 Hz, aromatic), 7.74 (2H, d, <italic toggle="yes">J</italic> = 8.60 Hz, aromatic), 8.38 (2H, d, <italic toggle="yes">J</italic> = 8.60 Hz, aromatic), 8.89 (2H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.77 (CH<sub>2</sub>, pyrazoline C<sub>4</sub>), 55.95 (2CH<sub>3</sub>, OCH<sub>3</sub>), 60.34 (CH, pyrazoline C<sub>5</sub>), 106.99 (CH, thiazole C<sub>5</sub>), 109.06 (CH, aromatic), 110.87 (CH, aromatic), 120.43 (CH, aromatic), 122.11 (C, aromatic), 123.79 (C, aromatic), 126.37 (2C, aromatic), 128.96 (3CH, aromatic), 129.61 (3CH, aromatic), 132.84 (2CH, aromatic), 135.29 (C, aromatic), 137.09 (C, aromatic), 139.04 (C, aromatic), 149.46 (C, aromatic), 149.75 (C, thiazole C<sub>4</sub>), 150.36 (C, aromatic), 152.48 (C, pyrazoline C<sub>3</sub>), 156.48 (2CH, aromatic), 161.52 (C, aromatic), 165.40 (C, thiazole C<sub>2</sub>). HRMS (FAB) calcd. for C<sub>31</sub>H<sub>23</sub>O<sub>2</sub>N<sub>6</sub>ClS [M+H]<sup>+</sup>: m/z = 578.1292; found: 578.1288. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S23&#x02013;S25</xref>).</p><p>2-(5-(2-(4-Chlorophenyl)pyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1<italic toggle="yes">H</italic>-pyrazol-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazole (<bold>BH-7</bold>)</p><p>Yield: 78%. M.p. 187.2 &#x000b0;C</p><p><sup>1</sup>H NMR (500 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 3.39 (1H, dd, <italic toggle="yes">J<sub>AB</sub></italic> = 17.20 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 6.55 Hz, C<sub>4</sub>-H<sub>A</sub> pyrazoline), 3.85&#x02013;3.92 (1H, m, C<sub>4</sub>-H<sub>B</sub> pyrazoline), 3.94 (3H, s, OCH<sub>3</sub>), 3.99 (3H, s, OCH<sub>3</sub>), 5.67 (1H, dd, <italic toggle="yes">J<sub>BX</sub></italic> = 12.00 Hz, <italic toggle="yes">J<sub>AX</sub></italic> = 7.20 Hz, C<sub>5</sub>-H<sub>X</sub> pyrazoline), 6.97 (1H, s, aromatic), 7.16 (1H, d, <italic toggle="yes">J</italic> = 8.55 Hz, aromatic), 7.43&#x02013;7.49 (4H, m, aromatic), 7.58 (2H, t, <italic toggle="yes">J</italic> = 8.25 Hz, aromatic), 7.76 (2H, t, <italic toggle="yes">J</italic> = 10.50 Hz, aromatic), 8.37&#x02013;8.42 (2H, m, aromatic), 8.89 (2H, s, aromatic). <sup>13</sup>C NMR (125 MHz, <italic toggle="yes">CDCl</italic><sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> (ppm): 42.42 (CH<sub>2</sub>, pyrazoline C<sub>4</sub>), 58.79 (2CH<sub>3</sub>, OCH<sub>3</sub>), 60.25 (CH, pyrazoline C<sub>5</sub>), 106.97 (CH, thiazole C<sub>5</sub>), 108.66 (CH, aromatic), 110.66 (CH, aromatic), 120.34 (CH, aromatic), 122.61 (C, aromatic), 123.42 (C, aromatic), 125.87 (2C, aromatic), 128.13 (2CH, aromatic), 128.79 (2CH, aromatic), 129.87 (2CH, aromatic), 132.79 (2CH, aromatic), 134.48 (C, aromatic), 135.70 (C, aromatic), 138.94 (C, aromatic), 148.92 (C, aromatic), 146.41 (C, thiazole C<sub>4</sub>), 151.37 (C, pyrazoline C<sub>3</sub>), 152.30 (C, aromatic), 155.99 (2CH, aromatic), 160.36 (C, aromatic), 164.09 (C, thiazole C<sub>2</sub>). HRMS (FAB) calcd. for C<sub>31</sub>H<sub>23</sub>O<sub>2</sub>N<sub>5</sub>ClF<sub>3</sub>S [M+H]<sup>+</sup>: m/z = 621.1213; found: 621.1205. (Spectral Data: <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Supplementary Information</xref>. <xref rid="app1-pharmaceuticals-18-00270" ref-type="app">Figures S26&#x02013;S28</xref>).</p></sec></sec><sec id="sec4dot2-pharmaceuticals-18-00270"><title>4.2. Cell Culture and Drug Treatment</title><p>Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) (Wako Pure Chemical Industries, Osaka, Japan) containing 10% fetal bovine serum (FBS) (Equitech-Bio, Kerrville, TX, USA) was used for the culture of A549 and MCF-7 human cancer cells, while RPMI 1640 (Wako Pure Chemical Industries) containing 10% FBS was used for the culture of Jurkat cells, derived from human leukemia. On the other hand, PBMCs (Precision Bioservices, Frederick, MD, USA) were incubated in RPMI 1640 supplemented with 10% human serum AB (HS) (Gemini, Woodland, CA, USA). All media also incorporated 89 &#x003bc;g/mL of streptomycin (Meiji Seika Pharma, Tokyo, Japan), and cells were maintained at 37 &#x000b0;C in a 95% air and 5% CO<sub>2</sub> humidified chamber. The microtiter tissue culture plates (24-well and 96-well) (Iwaki, Asahi Glass Co., Chiba, Japan) were used for cancer cells (4 &#x000d7; 10<sup>4</sup> cells/mL) and PBMCs (5 &#x000d7; 10<sup>5</sup> cells/mL), respectively. Prior to drug treatment, all of these cells were incubated for 72 h. The optimal cell density for cytotoxicity testing was established in preliminary experiments. The stock solutions of compounds and lapatinib (Sigma-Aldrich, St. Louis, MO, USA) (0.1 mM, 0.3 mM, 1 mM, 3 mM, and 10 mM) were prepared in dimethyl sulfoxide (DMSO; Wako Pure Chemical Industries), then applied to fresh culture medium. The final concentration of DMSO in the culture medium was adjusted to 1% [<xref rid="B61-pharmaceuticals-18-00270" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-18-00270" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceuticals-18-00270" ref-type="bibr">63</xref>].</p></sec><sec id="sec4dot3-pharmaceuticals-18-00270"><title>4.3. MTT Assay for Cytotoxicity of Compounds</title><p>The cellular reduction in MTT (Dojindo Molecular Technologies, Kumamoto, Japan) was measured as described in the literature with minor modifications [<xref rid="B61-pharmaceuticals-18-00270" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-18-00270" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceuticals-18-00270" ref-type="bibr">63</xref>]. The compounds and lapatinib were incubated with cells at final concentrations ranging from 1 to 100 &#x003bc;M for 72 h. MTT was then added at a final concentration 0.275 mg/mL and incubated for a further 4 h at 37 &#x000b0;C. The medium was removed and 100 &#x003bc;L DMSO was added to each well to dissolve the formazan crystals. The dissolved crystals were diluted (1:10) with DMSO, and 100 &#x003bc;L of the solution was transferred to a 96-well microtiter plate (Iwaki, Asahi Glass Co.). Absorbance was measured at 570 nm using an Infinitive M1000 microplate spectrophotometer (Tecan, Groding, Austria). Each concentration was tested in triplicate, and the IC<sub>50</sub> values were determined as the drug concentrations that reduced absorbance to 50% of the control values.</p></sec><sec id="sec4dot4-pharmaceuticals-18-00270"><title>4.4. Detection of Apoptotic and Necrotic Cells</title><p>Compound <bold>B-4</bold> at an IC<sub>50</sub> concentration was administered to A549 and MCF-7 cells for 24 h. After detachment from the plate with 0.05% trypsin and washing twice with 1&#x000d7; binding buffer, the cells were incubated for 20 min at r.t. in the dark with a staining solution bearing 50 &#x003bc;L 1&#x000d7; binding buffer, 4 &#x003bc;L FTIC annexin V solution, 4 &#x003bc;L ethidium homodimer III solution, and 4 &#x003bc;L Hoechst 33342 solution. The cells were washed with 1&#x000d7; binding buffer, fixed with 2% paraformaldehyde, washed with PBS, and analyzed by a Biorevo Fluorescence BZ-9000 (Keyence, Osaka, Japan) integrated fluorescence microscope [<xref rid="B61-pharmaceuticals-18-00270" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-18-00270" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceuticals-18-00270" ref-type="bibr">63</xref>].</p></sec><sec id="sec4dot5-pharmaceuticals-18-00270"><title>4.5. EGFR Inhibition Assay</title><p>The kinase profiling assay protocol (EGFR Kinase Enzyme System, V3831) was performed following the manufacturer&#x02019;s instructions (Promega Corporation, Madison, WI, USA) with minor modifications [<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>]. As per the protocol, 95 &#x003bc;L of 2.5&#x000d7; kinase buffer and 15 &#x003bc;L of 100 &#x003bc;M ATP solution were used for the dilution of the EGFR kinase (human, recombinant; amino acids 695&#x02013;end) and its substrate (4:1 Glu, Tyr). Kinase reactions were performed in a 384-well plate in the presence of 2 &#x003bc;L of kinase working stock, 2 &#x003bc;L of ATP/substrate working stock, and 1 &#x003bc;L of the test compound solution (1 &#x003bc;M and 1 &#x003bc;M) or 5% DMSO solution. After incubating for 2 h at r.t., kinase activity was assessed using the ADP-Glo Kinase Assay (Promega Corporation, Madison, WI, USA) following the manufacturer&#x02019;s instructions. Specifically, 5 &#x003bc;L of ADP-Glo Reagent was added to each well and incubated for 40 min, followed by the addition of 10 &#x003bc;L of Kinase Detection Reagent and further incubation for 30 min at room temperature. Luminescence was measured using the Infinite M1000 microplate reader (Tecan, Gr&#x000f6;dig, Austria) with an integration time of 0.5&#x02013;1 s to evaluate the kinase inhibitory effects of the compounds in a dose-dependent manner.</p></sec><sec id="sec4dot6-pharmaceuticals-18-00270"><title>4.6. Molecular Docking</title><p>A high resolution (1.50 &#x000c5;) X-ray structure of the EGFR complexed with and inhibitor (tak-285) was downloaded from the Protein Data Bank (PDB ID: 3POZ) [<xref rid="B64-pharmaceuticals-18-00270" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceuticals-18-00270" ref-type="bibr">65</xref>] and was prepared for molecular docking simulation using Schr&#x000f6;dinger&#x02019;s 2022-4 drug discovery software. While preparing the protein, the OPSL4 force filed was applied, with a convergence RMSD cut-off of 0.30 &#x000c5; for energy minimization, to ensure the stability and quality of the resultant protein for subsequent studies.</p><p>A grid box was generated centered on the native ligand tak-285 (03P) to identify the binding site of the EGFR. All the docking simulations were carried out using induced fit docking (IFD) protocol [<xref rid="B66-pharmaceuticals-18-00270" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceuticals-18-00270" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceuticals-18-00270" ref-type="bibr">68</xref>] with default settings.</p></sec><sec id="sec4dot7-pharmaceuticals-18-00270"><title>4.7. MD Simulations</title><p>Flare&#x02122; v9.0.0 [<xref rid="B69-pharmaceuticals-18-00270" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-18-00270" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceuticals-18-00270" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceuticals-18-00270" ref-type="bibr">72</xref>] software by Cresset was used for molecular dynamics simulations, which is based on the OpenMM package [<xref rid="B73-pharmaceuticals-18-00270" ref-type="bibr">73</xref>]. An orthogonal solvent box was generated using three point extended simple point charge (SPC/E) [<xref rid="B74-pharmaceuticals-18-00270" ref-type="bibr">74</xref>] explicit water solvent model. AMBER was employed as the force field used during the calculation, and the GAFF2 version was selected for small molecules. Seven sodium ions were placed as counterions to neutralize the system. The ionic strength of the explicit solvent box was adjusted to 0.15 M NaCl. The Particle Mesh Ewald (PME) method was used to consider all long-range electrostatic interactions. The reporting frequency (number of time steps between trajectory frames) was adjusted to 20,000. Periodic boundary conditions were applied and finally, the production stage was run for 300 ns under an isothermal&#x02013;isobaric ensemble (NPT).</p></sec><sec id="sec4dot8-pharmaceuticals-18-00270"><title>4.8. In Silico ADME Prediction</title><p>QikProp [<xref rid="B59-pharmaceuticals-18-00270" ref-type="bibr">59</xref>] and the SwissADME web tool [<xref rid="B60-pharmaceuticals-18-00270" ref-type="bibr">60</xref>] were used to estimate the pharmacokinetic determinants of <bold>B-4</bold>, as previously explained [<xref rid="B75-pharmaceuticals-18-00270" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-18-00270" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceuticals-18-00270" ref-type="bibr">77</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceuticals-18-00270"><title>5. Conclusions</title><p>New pyrimidine-containing compounds (chalcone derivative (<bold>B-4</bold>), pyrazoline&#x02013;carbothioamide (<bold>B-9</bold>), and pyrazoline&#x02013;thiazole hybrids (<bold>BH1-7</bold>)) have been prepared and structurally resolved using our well-established methods. These molecules have been tested in A549 NSCLC and MCF-7 breast cancer cells. Indicating the important role of the chalcone moiety, <bold>B-4</bold> induced cytotoxicity as the most potent anticancer agent against both A549 and MCF-7 cells. In addition, <bold>B-4</bold> revealed a low level of cytotoxicity to healthy cells (PBMCs). <bold>B-4</bold> was shown to induce apoptosis in NSCLC and breast cancer cells and to significantly inhibit the EGFR. Molecular dynamics simulations run for 300 ns revealed strong, favorable, and stable interactions between <bold>B-4</bold> and the EGFR. The potential of <bold>B-4</bold> as a drug candidate for both anti-NSCLC and anti-breast cancer activity studies was highlighted by in silico ADME prediction. <bold>B-4</bold> can be identified as a small-molecule EGFR inhibitor to be effective against NSCLC and breast cancer for future studies.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank TUBITAK and the European Union&#x02019;s Horizon Europe research and innovation programme for their support.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00270"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020270/s1">https://www.mdpi.com/article/10.3390/ph18020270/s1</uri>, Figure S1: The superimposed conformations of X-ray co-crystal structure (orange) and the docked pose (green) generated after IFD protocol; Figure S2: <sup>1</sup>H NMR Spectrum of <bold>B-4</bold>; Figure S3: <sup>13</sup>C NMR Spectrum of <bold>B-4</bold>; Figure S4: Mass Spectrum of <bold>B-4</bold>; Figure S5: <sup>1</sup>H NMR Spectrum of <bold>B-9</bold>; Figure S6: <sup>13</sup>C NMR Spectrum of <bold>B-9</bold>; Figure S7: Mass Spectrum of <bold>B-9</bold>; Figure S8: <sup>1</sup>H NMR Spectrum of <bold>BH-1</bold>; Figure S9: <sup>13</sup>C NMR Spectrum of <bold>BH-1</bold>; Figure S10: Mass Spectrum of <bold>BH-1</bold>; Figure S11: <sup>1</sup>H NMR Spectrum of <bold>BH-2</bold>; Figure S12: <sup>13</sup>C NMR Spectrum of <bold>BH-2</bold>; Figure S13: Mass Spectrum of <bold>BH-2</bold>; Figure S14: <sup>1</sup>H NMR Spectrum of <bold>BH-3</bold>; Figure S15: <sup>13</sup>C NMR Spectrum of <bold>BH-3</bold>; Figure S16: Mass Spectrum of <bold>BH-3</bold>; Figure S17: <sup>1</sup>H NMR Spectrum of <bold>BH-4</bold>; Figure S18: <sup>13</sup>C NMR Spectrum of <bold>BH-4</bold>; Figure S19: Mass Spectrum of <bold>BH-4</bold>; Figure S20: <sup>1</sup>H NMR Spectrum of <bold>BH-5</bold>; Figure S21: <sup>13</sup>C NMR Spectrum of <bold>BH-5</bold>; Figure S22: Mass Spectrum of <bold>BH-5</bold>; Figure S23: <sup>1</sup>H NMR Spectrum of <bold>BH-6</bold>; Figure S24: <sup>13</sup>C NMR Spectrum of <bold>BH-6</bold>; Figure S25: Mass Spectrum of <bold>BH-6</bold>; Figure S26: <sup>1</sup>H NMR Spectrum of <bold>BH-7</bold>; Figure S27: <sup>13</sup>C NMR Spectrum of <bold>BH-7</bold>; Figure S28: Mass Spectrum of <bold>BH-7.</bold></p><supplementary-material id="pharmaceuticals-18-00270-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00270-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, F.R., B.S. and H.C.; methodology, F.R., B.S., C.S.-G., F.B., A.E. and H.C.; software, F.R., B.S., C.S.-G., F.B., A.E. and H.C. validation, F.R., B.S., C.S.-G., F.B., A.E. and H.C.; formal analysis, F.R., B.S. and H.C.; investigation, F.R., B.S., E.T., F.B., A.E., M.F. and H.C.; resources, H.C.; data curation, B.S. and H.C.; writing&#x02014;original draft preparation, F.R., B.S., E.T., F.B., A.E., M.F. and H.C.; writing&#x02014;review and editing, F.R., B.S., E.T., C.S.-G., M.C., A.F.T., F.B., A.E., M.O., M.F., H.D. and H.C visualization, F.R., B.S., F.B., A.E. and H.C.; supervision, H.C.; project administration, H.C.; funding acquisition, H.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-pharmaceuticals-18-00270" ref-type="app">supplementary material</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest with Science Farm Ltd.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00270"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Kratzer</surname><given-names>T.B.</given-names></name>
<name><surname>Giaquinto</surname><given-names>A.N.</given-names></name>
<name><surname>Sung</surname><given-names>H.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
</person-group><article-title>Cancer statistics, 2025</article-title><source>CA Cancer J. Clin.</source><year>2025</year><volume>75</volume><fpage>10</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.3322/caac.21871</pub-id><pub-id pub-id-type="pmid">39817679</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00270"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bidram</surname><given-names>E.</given-names></name>
<name><surname>Esmaeili</surname><given-names>Y.</given-names></name>
<name><surname>Ranji-Burachaloo</surname><given-names>H.</given-names></name>
<name><surname>Al-Zaubai</surname><given-names>N.</given-names></name>
<name><surname>Zarrabi</surname><given-names>A.</given-names></name>
<name><surname>Stewart</surname><given-names>A.</given-names></name>
<name><surname>Dunstan</surname><given-names>D.E.</given-names></name>
</person-group><article-title>A concise review on cancer treatment methods and delivery systems</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2019</year><volume>54</volume><fpage>101350</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101350</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-18-00270"><label>3.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Ferlay</surname><given-names>J.</given-names></name>
<name><surname>Ervik</surname><given-names>M.</given-names></name>
<name><surname>Lam</surname><given-names>F.</given-names></name>
<name><surname>Laversanne</surname><given-names>M.</given-names></name>
<name><surname>Colombet</surname><given-names>M.</given-names></name>
<name><surname>Mery</surname><given-names>L.</given-names></name>
<name><surname>Pi&#x000f1;eros</surname><given-names>M.</given-names></name>
<name><surname>Znaor</surname><given-names>A.</given-names></name>
<name><surname>Soerjomataram</surname><given-names>I.</given-names></name>
<name><surname>Bray</surname><given-names>F.</given-names></name>
</person-group><article-title>Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://gco.iarc.who.int/today" ext-link-type="uri">https://gco.iarc.who.int/today</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-24">(accessed on 24 January 2025)</date-in-citation></element-citation></ref><ref id="B4-pharmaceuticals-18-00270"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walser</surname><given-names>T.</given-names></name>
<name><surname>Cui</surname><given-names>X.</given-names></name>
<name><surname>Yanagawa</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.M.</given-names></name>
<name><surname>Heinrich</surname><given-names>E.</given-names></name>
<name><surname>Lee</surname><given-names>G.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Dubinett</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Smoking and lung cancer: The role of inflammation</article-title><source>Proc. Am. Thorac. Soc.</source><year>2008</year><volume>5</volume><fpage>811</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1513/pats.200809-100TH</pub-id><pub-id pub-id-type="pmid">19017734</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00270"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Midha</surname><given-names>A.</given-names></name>
<name><surname>Dearden</surname><given-names>S.</given-names></name>
<name><surname>McCormack</surname><given-names>R.</given-names></name>
</person-group><article-title>EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII)</article-title><source>Am. J. Cancer Res.</source><year>2015</year><volume>5</volume><fpage>2892</fpage><lpage>2911</lpage><pub-id pub-id-type="pmid">26609494</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00270"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mani</surname><given-names>D.</given-names></name>
<name><surname>Haigentz</surname><given-names>M.</given-names></name>
<name><surname>Aboulafia</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Lung cancer in HIV Infection</article-title><source>Clin. Lung Cancer</source><year>2012</year><volume>13</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2011.05.005</pub-id><pub-id pub-id-type="pmid">21802373</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00270"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubin</surname><given-names>S.</given-names></name>
<name><surname>Griffin</surname><given-names>D.</given-names></name>
</person-group><article-title>Lung Cancer in Non-Smokers</article-title><source>Mo. Med.</source><year>2020</year><volume>117</volume><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">32848276</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00270"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Florez</surname><given-names>N.</given-names></name>
<name><surname>Kiel</surname><given-names>L.</given-names></name>
<name><surname>Riano</surname><given-names>I.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>DeCarli</surname><given-names>K.</given-names></name>
<name><surname>Dhawan</surname><given-names>N.</given-names></name>
<name><surname>Franco</surname><given-names>I.</given-names></name>
<name><surname>Odai-Afotey</surname><given-names>A.</given-names></name>
<name><surname>Meza</surname><given-names>K.</given-names></name>
<name><surname>Swami</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Lung cancer in women: The past, present, and future</article-title><source>Clin. Lung Cancer</source><year>2024</year><volume>25</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2023.10.007</pub-id><pub-id pub-id-type="pmid">37940410</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00270"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Travis</surname><given-names>W.D.</given-names></name>
<name><surname>Brambilla</surname><given-names>E.</given-names></name>
<name><surname>Burke</surname><given-names>A.P.</given-names></name>
<name><surname>Marx</surname><given-names>A.</given-names></name>
<name><surname>Nicholson</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart</article-title><source>J. Thorac. Oncol.</source><year>2015</year><volume>10</volume><fpage>1240</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000663</pub-id><pub-id pub-id-type="pmid">26291007</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00270"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Miller</surname><given-names>K.D.</given-names></name>
<name><surname>Fuchs</surname><given-names>H.E.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
</person-group><article-title>Cancer statistics. 2021</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>7</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21654</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-18-00270"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sung</surname><given-names>H.</given-names></name>
<name><surname>Ferlay</surname><given-names>J.</given-names></name>
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Laversanne</surname><given-names>M.</given-names></name>
<name><surname>Soerjomataram</surname><given-names>I.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
<name><surname>Bray</surname><given-names>F.</given-names></name>
</person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00270"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Planchard</surname><given-names>D.</given-names></name>
<name><surname>Popat</surname><given-names>S.</given-names></name>
<name><surname>Kerr</surname><given-names>K.</given-names></name>
<name><surname>Novello</surname><given-names>S.</given-names></name>
<name><surname>Smit</surname><given-names>E.F.</given-names></name>
<name><surname>Faivre-Finn</surname><given-names>C.</given-names></name>
<name><surname>Mok</surname><given-names>T.S.</given-names></name>
<name><surname>Reck</surname><given-names>M.</given-names></name>
<name><surname>Van Schil</surname><given-names>P.E.</given-names></name>
<name><surname>Hellmann</surname><given-names>M.D.</given-names></name>
<etal/>
</person-group><article-title>Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title><source>Ann. Oncol.</source><year>2018</year><volume>29</volume><fpage>iv192</fpage><lpage>iv237</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy275</pub-id><pub-id pub-id-type="pmid">30285222</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00270"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miao</surname><given-names>H.</given-names></name>
<name><surname>Verkooijen</surname><given-names>H.M.</given-names></name>
<name><surname>Chia</surname><given-names>K.-S.</given-names></name>
<name><surname>Bouchardy</surname><given-names>C.</given-names></name>
<name><surname>Pukkala</surname><given-names>E.</given-names></name>
<name><surname>Lar&#x000f8;nningen</surname><given-names>S.</given-names></name>
<name><surname>Mellemkj&#x000e6;r</surname><given-names>L.</given-names></name>
<name><surname>Czene</surname><given-names>K.</given-names></name>
<name><surname>Hartman</surname><given-names>M.</given-names></name>
</person-group><article-title>Incidence and Outcome of Male Breast Cancer: An International Population-Based Study</article-title><source>J. Clin. Oncol.</source><year>2011</year><volume>29</volume><fpage>4381</fpage><lpage>4386</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.36.8902</pub-id><pub-id pub-id-type="pmid">21969512</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00270"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lehmann</surname><given-names>B.D.</given-names></name>
<name><surname>Pietenpol</surname><given-names>J.A.</given-names></name>
<name><surname>Tan</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Triple-negative breast cancer: Molecular subtypes and new targets for therapy</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2015</year><volume>35</volume><fpage>e31</fpage><lpage>e39</lpage><pub-id pub-id-type="doi">10.14694/EdBook_AM.2015.35.e31</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-18-00270"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tfayli</surname><given-names>A.</given-names></name>
<name><surname>Temraz</surname><given-names>S.</given-names></name>
<name><surname>Abou Mrad</surname><given-names>R.</given-names></name>
<name><surname>Shamseddine</surname><given-names>A.</given-names></name>
</person-group><article-title>Breast cancer in low- and middle-income countries: An emerging and challenging epidemic</article-title><source>J. Oncol.</source><year>2010</year><volume>2010</volume><fpage>490631</fpage><pub-id pub-id-type="doi">10.1155/2010/490631</pub-id><pub-id pub-id-type="pmid">21209708</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00270"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Costa Vieira</surname><given-names>R.A.</given-names></name>
<name><surname>Biller</surname><given-names>G.</given-names></name>
<name><surname>Uemura</surname><given-names>G.</given-names></name>
<name><surname>Ruiz</surname><given-names>C.A.</given-names></name>
<name><surname>Curado</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Breast cancer screening in developing countries</article-title><source>Clinics</source><year>2017</year><volume>72</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.6061/clinics/2017(04)09</pub-id><pub-id pub-id-type="pmid">28492725</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00270"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shulman</surname><given-names>L.N.</given-names></name>
<name><surname>Willett</surname><given-names>W.</given-names></name>
<name><surname>Sievers</surname><given-names>A.</given-names></name>
<name><surname>Knaul</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Breast cancer in developing countries: Opportunities for improved survival</article-title><source>J. Oncol.</source><year>2010</year><volume>2010</volume><fpage>595167</fpage><pub-id pub-id-type="doi">10.1155/2010/595167</pub-id><pub-id pub-id-type="pmid">21253541</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00270"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>H.</given-names></name>
<name><surname>Bai</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping</article-title><source>J. Cancer</source><year>2017</year><volume>8</volume><fpage>3131</fpage><lpage>3141</lpage><pub-id pub-id-type="doi">10.7150/jca.18457</pub-id><pub-id pub-id-type="pmid">29158785</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00270"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diaz</surname><given-names>L.K.</given-names></name>
<name><surname>Cryns</surname><given-names>V.L.</given-names></name>
<name><surname>Symmans</surname><given-names>W.F.</given-names></name>
<name><surname>Sneige</surname><given-names>N.</given-names></name>
</person-group><article-title>Triple negative breast carcinoma and the basal phenotype: From expression profiling to clinical practice</article-title><source>Adv. Anat. Pathol.</source><year>2007</year><volume>14</volume><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1097/PAP.0b013e3181594733</pub-id><pub-id pub-id-type="pmid">18049131</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00270"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walter</surname><given-names>V.</given-names></name>
<name><surname>Fischer</surname><given-names>C.</given-names></name>
<name><surname>Deutsch</surname><given-names>T.M.</given-names></name>
<name><surname>Ersing</surname><given-names>C.</given-names></name>
<name><surname>Nees</surname><given-names>J.</given-names></name>
<name><surname>Sch&#x000fc;tz</surname><given-names>F.</given-names></name>
<name><surname>Fremd</surname><given-names>C.</given-names></name>
<name><surname>Grischke</surname><given-names>E.M.</given-names></name>
<name><surname>Sinn</surname><given-names>P.</given-names></name>
<name><surname>Brucker</surname><given-names>S.Y.</given-names></name>
<etal/>
</person-group><article-title>Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer</article-title><source>Breast Cancer Res. Treat.</source><year>2020</year><volume>183</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/s10549-020-05746-8</pub-id><pub-id pub-id-type="pmid">32613540</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00270"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ueno</surname><given-names>N.T.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
</person-group><article-title>Targeting EGFR in Triple Negative Breast Cancer</article-title><source>J. Cancer</source><year>2011</year><volume>2</volume><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.7150/jca.2.324</pub-id><pub-id pub-id-type="pmid">21716849</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00270"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wakelee</surname><given-names>H.</given-names></name>
<name><surname>Kelly</surname><given-names>K.</given-names></name>
<name><surname>Edelman</surname><given-names>M.J.</given-names></name>
</person-group><article-title>50 Years of progress in the systemic therapy of non-small cell lung cancer</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2014</year><volume>34</volume><fpage>177</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.14694/EdBook_AM.2014.34.177</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-18-00270"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciardiello</surname><given-names>F.</given-names></name>
<name><surname>Hirsch</surname><given-names>F.R.</given-names></name>
<name><surname>Pirker</surname><given-names>R.</given-names></name>
<name><surname>Felip</surname><given-names>E.</given-names></name>
<name><surname>Valencia</surname><given-names>C.</given-names></name>
<name><surname>Smit</surname><given-names>E.F.</given-names></name>
</person-group><article-title>The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer</article-title><source>Cancer Treat. Rev.</source><year>2024</year><volume>122</volume><fpage>102664</fpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2023.102664</pub-id><pub-id pub-id-type="pmid">38064878</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00270"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gluz</surname><given-names>O.</given-names></name>
<name><surname>Liedtke</surname><given-names>C.</given-names></name>
<name><surname>Gottschalk</surname><given-names>N.</given-names></name>
<name><surname>Pusztai</surname><given-names>L.</given-names></name>
<name><surname>Nitz</surname><given-names>U.</given-names></name>
<name><surname>Harbeck</surname><given-names>N.</given-names></name>
</person-group><article-title>Triple-negative breast cancer--current status and future directions</article-title><source>Ann. Oncol.</source><year>2009</year><volume>20</volume><fpage>1913</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp492</pub-id><pub-id pub-id-type="pmid">19901010</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00270"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Pinilla</surname><given-names>S.M.</given-names></name>
<name><surname>Sarri&#x000f3;</surname><given-names>D.</given-names></name>
<name><surname>Honrado</surname><given-names>E.</given-names></name>
<name><surname>Moreno-Bueno</surname><given-names>G.</given-names></name>
<name><surname>Hardisson</surname><given-names>D.</given-names></name>
<name><surname>Calero</surname><given-names>F.</given-names></name>
<name><surname>Ben&#x000ed;tez</surname><given-names>J.</given-names></name>
<name><surname>Palacios</surname><given-names>J.</given-names></name>
</person-group><article-title>Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas</article-title><source>J. Clin. Pathol.</source><year>2007</year><volume>60</volume><fpage>1006</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1136/jcp.2006.042143</pub-id><pub-id pub-id-type="pmid">17105822</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00270"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Sarkissyan</surname><given-names>M.</given-names></name>
<name><surname>Vadgama</surname><given-names>J.V.</given-names></name>
</person-group><article-title>Epithelial-Mesenchymal Transition and Breast Cancer</article-title><source>J. Clin. Med.</source><year>2016</year><volume>5</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.3390/jcm5020013</pub-id><pub-id pub-id-type="pmid">26821054</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00270"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bose</surname><given-names>P.</given-names></name>
<name><surname>Ozer</surname><given-names>H.</given-names></name>
</person-group><article-title>Neratinib: An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer</article-title><source>Expert Opin. Investig. Drugs</source><year>2009</year><volume>18</volume><fpage>1735</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1517/13543780903305428</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-18-00270"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uribe</surname><given-names>M.L.</given-names></name>
<name><surname>Marrocco</surname><given-names>I.</given-names></name>
<name><surname>Yarden</surname><given-names>Y.</given-names></name>
</person-group><article-title>EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>2748</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13112748</pub-id><pub-id pub-id-type="pmid">34206026</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00270"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sigismund</surname><given-names>S.</given-names></name>
<name><surname>Avanzato</surname><given-names>D.</given-names></name>
<name><surname>Lanzetti</surname><given-names>L.</given-names></name>
</person-group><article-title>Emerging functions of the EGFR in cancer</article-title><source>Mol. Oncol.</source><year>2018</year><volume>12</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12155</pub-id><pub-id pub-id-type="pmid">29124875</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00270"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seshacharyulu</surname><given-names>P.</given-names></name>
<name><surname>Ponnusamy</surname><given-names>M.P.</given-names></name>
<name><surname>Haridas</surname><given-names>D.</given-names></name>
<name><surname>Jain</surname><given-names>M.</given-names></name>
<name><surname>Ganti</surname><given-names>A.K.</given-names></name>
<name><surname>Batra</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Targeting the EGFR signaling pathway in cancer therapy</article-title><source>Expert Opin. Ther. Targets</source><year>2012</year><volume>16</volume><fpage>15</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1517/14728222.2011.648617</pub-id><pub-id pub-id-type="pmid">22239438</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00270"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>J.L.</given-names></name>
<name><surname>Hung</surname><given-names>M.C.</given-names></name>
</person-group><article-title>The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer</article-title><source>Cancer Metastasis Rev.</source><year>2016</year><volume>35</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1007/s10555-016-9649-6</pub-id><pub-id pub-id-type="pmid">27913999</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00270"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Fu</surname><given-names>L.</given-names></name>
</person-group><article-title>Mechanisms of resistance to EGFR tyrosine kinase inhibitors</article-title><source>Acta Pharm. Sin. B</source><year>2015</year><volume>5</volume><fpage>390</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2015.07.001</pub-id><pub-id pub-id-type="pmid">26579470</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00270"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>R.</given-names></name>
<name><surname>Kaur</surname><given-names>P.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>G.</given-names></name>
<name><surname>Mehndiratta</surname><given-names>S.</given-names></name>
<name><surname>Bedi</surname><given-names>P.M.</given-names></name>
<name><surname>Nepali</surname><given-names>K.</given-names></name>
</person-group><article-title>Anti-cancer pyrimidines in diverse scaffolds: A review of patent literature</article-title><source>Recent Pat. Anticancer Drug Discov.</source><year>2015</year><volume>10</volume><fpage>23</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.2174/1574892809666140917104502</pub-id><pub-id pub-id-type="pmid">25230072</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00270"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayati</surname><given-names>A.</given-names></name>
<name><surname>Moghimi</surname><given-names>S.</given-names></name>
<name><surname>Toolabi</surname><given-names>M.</given-names></name>
<name><surname>Foroumadi</surname><given-names>A.</given-names></name>
</person-group><article-title>Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy</article-title><source>Eur. J. Med. Chem.</source><year>2021</year><volume>221</volume><fpage>113523</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113523</pub-id><pub-id pub-id-type="pmid">33992931</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00270"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelgalil</surname><given-names>A.A.</given-names></name>
<name><surname>Alkahtani</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Lapatinib: A comprehensive profile</article-title><source>Profiles Drug Subst. Excip. Relat. Methodol.</source><year>2023</year><volume>48</volume><fpage>135</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">37061273</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00270"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>E.B.</given-names></name>
<name><surname>Guo</surname><given-names>Y.J.</given-names></name>
<name><surname>Zhang</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>Y.Z.</given-names></name>
<name><surname>Mack</surname><given-names>P.</given-names></name>
</person-group><article-title>Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives</article-title><source>Biochim. Biophys. Acta (BBA)-Protein Struct. Mol. Enzymol.</source><year>2001</year><volume>1550</volume><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/S0167-4838(01)00276-X</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-18-00270"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.J.</given-names></name>
<name><surname>Qian</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>D.D.</given-names></name>
<name><surname>Yang</surname><given-names>X.G.</given-names></name>
<name><surname>Zhu</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Synthesis, molecular modeling and biological evaluation of chalcone thiosemicarbazide derivatives as novel anticancer agents</article-title><source>Eur. J. Med. Chem.</source><year>2011</year><volume>46</volume><fpage>4702</fpage><lpage>4708</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2011.07.016</pub-id><pub-id pub-id-type="pmid">21816517</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00270"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jandial</surname><given-names>D.D.</given-names></name>
<name><surname>Blair</surname><given-names>C.A.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Krill</surname><given-names>L.S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.B.</given-names></name>
<name><surname>Zi</surname><given-names>X.</given-names></name>
</person-group><article-title>Molecular targeted approaches to cancer therapy and prevention using chalcones</article-title><source>Curr. Cancer Drug Targets</source><year>2014</year><volume>14</volume><fpage>181</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.2174/1568009614666140122160515</pub-id><pub-id pub-id-type="pmid">24467530</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00270"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karthikeyan</surname><given-names>C.</given-names></name>
<name><surname>Moorthy</surname><given-names>N.S.</given-names></name>
<name><surname>Ramasamy</surname><given-names>S.</given-names></name>
<name><surname>Vanam</surname><given-names>U.</given-names></name>
<name><surname>Manivannan</surname><given-names>E.</given-names></name>
<name><surname>Karunagaran</surname><given-names>D.</given-names></name>
<name><surname>Trivedi</surname><given-names>P.</given-names></name>
</person-group><article-title>Advances in chalcones with anticancer activities</article-title><source>Recent Pat. Anticancer Drug Discov.</source><year>2015</year><volume>10</volume><fpage>97</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.2174/1574892809666140819153902</pub-id><pub-id pub-id-type="pmid">25138130</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00270"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Kodwani</surname><given-names>R.</given-names></name>
<name><surname>Kapoor</surname><given-names>S.</given-names></name>
<name><surname>Khare</surname><given-names>A.</given-names></name>
<name><surname>Bansal</surname><given-names>R.</given-names></name>
<name><surname>Khurana</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name>
<name><surname>Roy</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>A Review on Mechanisms of Anti Tumor Activity of Chalcones</article-title><source>Anticancer Agents Med. Chem.</source><year>2015</year><volume>16</volume><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.2174/1871520615666150518093144</pub-id><pub-id pub-id-type="pmid">25980813</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00270"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>WalyEldeen</surname><given-names>A.A.</given-names></name>
<name><surname>Sabet</surname><given-names>S.</given-names></name>
<name><surname>El-Shorbagy</surname><given-names>H.M.</given-names></name>
<name><surname>Abdelhamid</surname><given-names>I.A.</given-names></name>
<name><surname>Ibrahim</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer</article-title><source>Chem. Biol. Interact.</source><year>2023</year><volume>369</volume><elocation-id>110297</elocation-id><pub-id pub-id-type="doi">10.1016/j.cbi.2022.110297</pub-id><pub-id pub-id-type="pmid">36496109</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00270"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Narwal</surname><given-names>S.</given-names></name>
<name><surname>Devi</surname><given-names>B.</given-names></name>
<name><surname>Dhanda</surname><given-names>T.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Tahlan</surname><given-names>S.</given-names></name>
</person-group><article-title>Exploring Chalcone Derivatives: Synthesis and Their Therapeutic Potential</article-title><source>J. Mol. Struct.</source><year>2024</year><volume>1303</volume><fpage>137554</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2024.137554</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-18-00270"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>M.F.</given-names></name>
<name><surname>Hassaneen</surname><given-names>H.M.</given-names></name>
<name><surname>Abdelhamid</surname><given-names>I.A.</given-names></name>
</person-group><article-title>Cytotoxicity, molecular modeling, cell cycle arrest, and apoptotic induction induced by novel tetrahydro-[1,2,4]triazolo[3,4-a]isoquinoline chalcones</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>143</volume><fpage>532</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.11.045</pub-id><pub-id pub-id-type="pmid">29207336</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00270"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanachai</surname><given-names>K.</given-names></name>
<name><surname>Aiebchun</surname><given-names>T.</given-names></name>
<name><surname>Mahalapbutr</surname><given-names>P.</given-names></name>
<name><surname>Seetaha</surname><given-names>S.</given-names></name>
<name><surname>Tabtimmai</surname><given-names>L.</given-names></name>
<name><surname>Maitarad</surname><given-names>P.</given-names></name>
<name><surname>Xenikakis</surname><given-names>I.</given-names></name>
<name><surname>Geronikaki</surname><given-names>A.</given-names></name>
<name><surname>Choowongkomon</surname><given-names>K.</given-names></name>
<name><surname>Rungrotmongkol</surname><given-names>T.</given-names></name>
</person-group><article-title>Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives</article-title><source>RSC Med. Chem.</source><year>2021</year><volume>12</volume><fpage>430</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1039/D0MD00436G</pub-id><pub-id pub-id-type="pmid">34046625</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00270"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alswah</surname><given-names>M.</given-names></name>
<name><surname>Bayoumi</surname><given-names>A.H.</given-names></name>
<name><surname>Elgamal</surname><given-names>K.</given-names></name>
<name><surname>Elmorsy</surname><given-names>A.</given-names></name>
<name><surname>Ihmaid</surname><given-names>S.</given-names></name>
<name><surname>Ahmed</surname><given-names>H.E.A.</given-names></name>
</person-group><article-title>Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects</article-title><source>Molecules</source><year>2017</year><volume>23</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23010048</pub-id><pub-id pub-id-type="pmid">29280968</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00270"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abou-Zied</surname><given-names>H.A.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.M.</given-names></name>
<name><surname>Mohamed</surname><given-names>M.F.A.</given-names></name>
<name><surname>Hayallah</surname><given-names>A.M.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>M.</given-names></name>
</person-group><article-title>EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules</article-title><source>Bioorg. Chem.</source><year>2019</year><volume>89</volume><elocation-id>102997</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2019.102997</pub-id><pub-id pub-id-type="pmid">31136902</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00270"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohassab</surname><given-names>A.M.</given-names></name>
<name><surname>Hassan</surname><given-names>H.A.</given-names></name>
<name><surname>Abdelhamid</surname><given-names>D.</given-names></name>
<name><surname>Gouda</surname><given-names>A.M.</given-names></name>
<name><surname>Youssif</surname><given-names>B.G.M.</given-names></name>
<name><surname>Tateishi</surname><given-names>H.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>M.</given-names></name>
</person-group><article-title>Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases</article-title><source>Bioorg. Chem.</source><year>2021</year><volume>106</volume><elocation-id>104510</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.104510</pub-id><pub-id pub-id-type="pmid">33279248</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00270"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Havrylyuk</surname><given-names>D.</given-names></name>
<name><surname>Roman</surname><given-names>O.</given-names></name>
<name><surname>Lesyk</surname><given-names>R.</given-names></name>
</person-group><article-title>Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline-thiazolidine-based hybrids</article-title><source>Eur. J. Med. Chem.</source><year>2016</year><volume>113</volume><fpage>145</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.02.030</pub-id><pub-id pub-id-type="pmid">26922234</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00270"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>B.</given-names></name>
<name><surname>Singh</surname><given-names>V.J.</given-names></name>
<name><surname>Chawla</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress</article-title><source>Bioorg. Chem.</source><year>2021</year><volume>116</volume><elocation-id>105393</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.105393</pub-id><pub-id pub-id-type="pmid">34628226</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00270"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lv</surname><given-names>P.C.</given-names></name>
<name><surname>Li</surname><given-names>D.D.</given-names></name>
<name><surname>Li</surname><given-names>Q.S.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Xiao</surname><given-names>Z.P.</given-names></name>
<name><surname>Zhu</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2011</year><volume>21</volume><fpage>5374</fpage><lpage>5377</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.07.010</pub-id><pub-id pub-id-type="pmid">21802290</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00270"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>George</surname><given-names>R.F.</given-names></name>
<name><surname>Samir</surname><given-names>E.M.</given-names></name>
<name><surname>Abdelhamed</surname><given-names>M.N.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>H.A.</given-names></name>
<name><surname>Abbas</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors</article-title><source>Bioorg. Chem.</source><year>2019</year><volume>83</volume><fpage>186</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2018.10.038</pub-id><pub-id pub-id-type="pmid">30380447</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00270"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sever</surname><given-names>B.</given-names></name>
<name><surname>Alt&#x00131;ntop</surname><given-names>M.D.</given-names></name>
<name><surname>Radwan</surname><given-names>M.O.</given-names></name>
<name><surname>&#x000d6;zdemir</surname><given-names>A.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>Ciftci</surname><given-names>H.I.</given-names></name>
</person-group><article-title>Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>182</volume><fpage>111648</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.111648</pub-id><pub-id pub-id-type="pmid">31493743</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00270"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelsalam</surname><given-names>E.A.</given-names></name>
<name><surname>Abd El-Hafeez</surname><given-names>A.A.</given-names></name>
<name><surname>Eldehna</surname><given-names>W.M.</given-names></name>
<name><surname>El Hassab</surname><given-names>M.A.</given-names></name>
<name><surname>Marzouk</surname><given-names>H.M.M.</given-names></name>
<name><surname>Elaasser</surname><given-names>M.M.</given-names></name>
<name><surname>Abou Taleb</surname><given-names>N.A.</given-names></name>
<name><surname>Amin</surname><given-names>K.M.</given-names></name>
<name><surname>Abdel-Aziz</surname><given-names>H.A.</given-names></name>
<name><surname>Ghosh</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2022</year><volume>37</volume><fpage>2265</fpage><lpage>2282</lpage><pub-id pub-id-type="doi">10.1080/14756366.2022.2104841</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-18-00270"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fakhry</surname><given-names>M.M.</given-names></name>
<name><surname>Mahmoud</surname><given-names>K.</given-names></name>
<name><surname>Nafie</surname><given-names>M.S.</given-names></name>
<name><surname>Noor</surname><given-names>A.O.</given-names></name>
<name><surname>Hareeri</surname><given-names>R.H.</given-names></name>
<name><surname>Salama</surname><given-names>I.</given-names></name>
<name><surname>Kishk</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7 Cancer Cells</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>1245</elocation-id><pub-id pub-id-type="doi">10.3390/ph15101245</pub-id><pub-id pub-id-type="pmid">36297358</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-18-00270"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c7;ift&#x000e7;i</surname><given-names>H.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>Sever</surname><given-names>B.</given-names></name>
</person-group><article-title>New naphthalene-linked pyrazoline-thiazole hybrids as prominent antilung and antibreast cancer inhibitors</article-title><source>Turk. J. Chem.</source><year>2024</year><volume>48</volume><fpage>856</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.55730/1300-0527.3704</pub-id><pub-id pub-id-type="pmid">39780846</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-18-00270"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ece</surname><given-names>A.</given-names></name>
</person-group><article-title>Computer-aided drug design</article-title><source>BMC Chem.</source><year>2023</year><volume>17</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/s13065-023-00939-w</pub-id><pub-id pub-id-type="pmid">36964610</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-18-00270"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ba&#x0015f;o&#x0011f;lu</surname><given-names>F.</given-names></name>
<name><surname>Ulusoy-G&#x000fc;zeldemirci</surname><given-names>N.</given-names></name>
<name><surname>Akal&#x00131;n-&#x000c7;ift&#x000e7;i</surname><given-names>G.</given-names></name>
<name><surname>&#x000c7;etinkaya</surname><given-names>S.</given-names></name>
<name><surname>Ece</surname><given-names>A.</given-names></name>
</person-group><article-title>Novel imidazo [2,1-<italic toggle="yes">b</italic>] thiazole-based anticancer agents as potential focal adhesion kinase inhibitors: Synthesis, in silico and in vitro evaluation</article-title><source>Chem. Biol. Drug Des.</source><year>2021</year><volume>98</volume><fpage>270</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1111/cbdd.13896</pub-id><pub-id pub-id-type="pmid">34021971</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-18-00270"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Efeoglu</surname><given-names>C.</given-names></name>
<name><surname>Taskin</surname><given-names>S.</given-names></name>
<name><surname>Selcuk</surname><given-names>O.</given-names></name>
<name><surname>Celik</surname><given-names>B.</given-names></name>
<name><surname>Tumkaya</surname><given-names>E.</given-names></name>
<name><surname>Ece</surname><given-names>A.</given-names></name>
<name><surname>Sari</surname><given-names>H.</given-names></name>
<name><surname>Seferoglu</surname><given-names>Z.</given-names></name>
<name><surname>Ayaz</surname><given-names>F.</given-names></name>
<name><surname>Nural</surname><given-names>Y.</given-names></name>
</person-group><article-title>Synthesis, anti-inflammatory activity, inverse molecular docking, and acid dissociation constants of new naphthoquinone-thiazole hybrids</article-title><source>Bioorg. Med. Chem.</source><year>2023</year><volume>95</volume><elocation-id>117510</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2023.117510</pub-id><pub-id pub-id-type="pmid">37926047</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-18-00270"><label>59.</label><element-citation publication-type="book"><source>Schr&#x000f6;dinger Release 2016-2: QikProp</source><publisher-name>Schr&#x000f6;dinger, LLC</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B60-pharmaceuticals-18-00270"><label>60.</label><element-citation publication-type="webpage"><article-title>SwissADME</article-title><comment>Available online: <ext-link xlink:href="http://www.swissadme.ch/" ext-link-type="uri">http://www.swissadme.ch/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-23">(accessed on 23 January 2025)</date-in-citation></element-citation></ref><ref id="B61-pharmaceuticals-18-00270"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bayrak</surname><given-names>N.</given-names></name>
<name><surname>Sever</surname><given-names>B.</given-names></name>
<name><surname>Ciftci</surname><given-names>H.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>TuYuN</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Scaffold Hopping and Structural Modification of NSC 663284: Discovery of Potent (Non)Halogenated Aminobenzoquinones</article-title><source>Biomedicines</source><year>2023</year><volume>12</volume><elocation-id>50</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines12010050</pub-id><pub-id pub-id-type="pmid">38255157</pub-id>
</element-citation></ref><ref id="B62-pharmaceuticals-18-00270"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bayrak</surname><given-names>N.</given-names></name>
<name><surname>Ciftci</surname><given-names>H.I.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>M.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>H.</given-names></name>
<name><surname>Sever</surname><given-names>B.</given-names></name>
<name><surname>Tateishi</surname><given-names>H.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>Tuyun</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs</article-title><source>Chem. Biol. Interact.</source><year>2021</year><volume>345</volume><elocation-id>109555</elocation-id><pub-id pub-id-type="doi">10.1016/j.cbi.2021.109555</pub-id><pub-id pub-id-type="pmid">34146539</pub-id>
</element-citation></ref><ref id="B63-pharmaceuticals-18-00270"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciftci</surname><given-names>H.I.</given-names></name>
<name><surname>Bayrak</surname><given-names>N.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>M.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>H.</given-names></name>
<name><surname>Sever</surname><given-names>B.</given-names></name>
<name><surname>Tateishi</surname><given-names>H.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>Tuyun</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs</article-title><source>Bioorg. Chem.</source><year>2021</year><volume>114</volume><elocation-id>105160</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.105160</pub-id><pub-id pub-id-type="pmid">34328861</pub-id>
</element-citation></ref><ref id="B64-pharmaceuticals-18-00270"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aertgeerts</surname><given-names>K.</given-names></name>
<name><surname>Skene</surname><given-names>R.</given-names></name>
<name><surname>Yano</surname><given-names>J.</given-names></name>
<name><surname>Sang</surname><given-names>B.C.</given-names></name>
<name><surname>Zou</surname><given-names>H.</given-names></name>
<name><surname>Snell</surname><given-names>G.</given-names></name>
<name><surname>Jennings</surname><given-names>A.</given-names></name>
<name><surname>Iwamoto</surname><given-names>K.</given-names></name>
<name><surname>Habuka</surname><given-names>N.</given-names></name>
<name><surname>Hirokawa</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>18756</fpage><lpage>18765</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.206193</pub-id><pub-id pub-id-type="pmid">21454582</pub-id>
</element-citation></ref><ref id="B65-pharmaceuticals-18-00270"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ba&#x0015f;aran</surname><given-names>E.</given-names></name>
<name><surname>K&#x000f6;pr&#x000fc;</surname><given-names>S.</given-names></name>
<name><surname>Akko&#x000e7;</surname><given-names>S.</given-names></name>
<name><surname>T&#x000fc;rkmeno&#x0011f;lu</surname><given-names>B.</given-names></name>
</person-group><article-title>Investigation of Newly Synthesized Fluorinated Isatin-Hydrazones by In Vitro Antiproliferative Activity, Molecular Docking, ADME Analysis, and e-Pharmacophore Modeling</article-title><source>ACS Omega</source><year>2024</year><volume>9</volume><fpage>26503</fpage><lpage>26518</lpage><pub-id pub-id-type="doi">10.1021/acsomega.4c03014</pub-id><pub-id pub-id-type="pmid">38911768</pub-id>
</element-citation></ref><ref id="B66-pharmaceuticals-18-00270"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farid</surname><given-names>R.</given-names></name>
<name><surname>Day</surname><given-names>T.</given-names></name>
<name><surname>Friesner</surname><given-names>R.A.</given-names></name>
<name><surname>Pearlstein</surname><given-names>R.A.</given-names></name>
</person-group><article-title>New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies</article-title><source>Bioorg. Med. Chem.</source><year>2006</year><volume>14</volume><fpage>3160</fpage><lpage>3173</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2005.12.032</pub-id><pub-id pub-id-type="pmid">16413785</pub-id>
</element-citation></ref><ref id="B67-pharmaceuticals-18-00270"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sherman</surname><given-names>W.</given-names></name>
<name><surname>Day</surname><given-names>T.</given-names></name>
<name><surname>Jacobson</surname><given-names>M.P.</given-names></name>
<name><surname>Friesner</surname><given-names>R.A.</given-names></name>
<name><surname>Farid</surname><given-names>R.</given-names></name>
</person-group><article-title>Novel procedure for modeling ligand/receptor induced fit effects</article-title><source>J. Med. Chem.</source><year>2006</year><volume>49</volume><fpage>534</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1021/jm050540c</pub-id><pub-id pub-id-type="pmid">16420040</pub-id>
</element-citation></ref><ref id="B68-pharmaceuticals-18-00270"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sherman</surname><given-names>W.</given-names></name>
<name><surname>Beard</surname><given-names>H.S.</given-names></name>
<name><surname>Farid</surname><given-names>R.</given-names></name>
</person-group><article-title>Use of an induced fit receptor structure in virtual screening</article-title><source>Chem. Biol. Drug Des.</source><year>2006</year><volume>67</volume><fpage>83</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2005.00327.x</pub-id><pub-id pub-id-type="pmid">16492153</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-18-00270"><label>69.</label><element-citation publication-type="webpage"><article-title><italic toggle="yes">Flare&#x02122;</italic>, v9.0.0, Cresset<sup>&#x000ae;</sup>: Litlington, Cambridgeshire, UK</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.cresset-group.com/flare/" ext-link-type="uri">https://www.cresset-group.com/flare/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-23">(accessed on 23 January 2025)</date-in-citation></element-citation></ref><ref id="B70-pharmaceuticals-18-00270"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheeseright</surname><given-names>T.</given-names></name>
<name><surname>Mackey</surname><given-names>M.</given-names></name>
<name><surname>Rose</surname><given-names>S.</given-names></name>
<name><surname>Vinter</surname><given-names>A.</given-names></name>
</person-group><article-title>Molecular Field Extrema as Descriptors of Biological Activity: Definition and Validation</article-title><source>J. Chem. Inf. Model.</source><year>2006</year><volume>46</volume><fpage>665</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1021/ci050357s</pub-id><pub-id pub-id-type="pmid">16562997</pub-id>
</element-citation></ref><ref id="B71-pharmaceuticals-18-00270"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>M.R.</given-names></name>
<name><surname>Mackey</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein-Ligand Complexes</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>3036</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01925</pub-id><pub-id pub-id-type="pmid">30807144</pub-id>
</element-citation></ref><ref id="B72-pharmaceuticals-18-00270"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuhn</surname><given-names>M.</given-names></name>
<name><surname>Firth-Clark</surname><given-names>S.</given-names></name>
<name><surname>Tosco</surname><given-names>P.</given-names></name>
<name><surname>Mey</surname><given-names>A.S.J.S.</given-names></name>
<name><surname>Mackey</surname><given-names>M.</given-names></name>
<name><surname>Michel</surname><given-names>J.</given-names></name>
</person-group><article-title>Assessment of Binding Affinity via Alchemical Free-Energy Calculations</article-title><source>J. Chem. Inf. Model.</source><year>2020</year><volume>60</volume><fpage>3120</fpage><lpage>3130</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.0c00165</pub-id><pub-id pub-id-type="pmid">32437145</pub-id>
</element-citation></ref><ref id="B73-pharmaceuticals-18-00270"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eastman</surname><given-names>P.</given-names></name>
<name><surname>Swails</surname><given-names>J.</given-names></name>
<name><surname>Chodera</surname><given-names>J.D.</given-names></name>
<name><surname>McGibbon</surname><given-names>R.T.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Beauchamp</surname><given-names>K.A.</given-names></name>
<name><surname>Wang</surname><given-names>L.P.</given-names></name>
<name><surname>Simmonett</surname><given-names>A.C.</given-names></name>
<name><surname>Harrigan</surname><given-names>M.P.</given-names></name>
<name><surname>Stern</surname><given-names>C.D.</given-names></name>
<etal/>
</person-group><article-title>OpenMM 7: Rapid development of high performance algorithms for molecular dynamics</article-title><source>PLoS Comput. Biol.</source><year>2017</year><volume>13</volume><elocation-id>e1005659</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005659</pub-id><pub-id pub-id-type="pmid">28746339</pub-id>
</element-citation></ref><ref id="B74-pharmaceuticals-18-00270"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berendsen</surname><given-names>H.J.</given-names></name>
<name><surname>Grigera</surname><given-names>J.R.</given-names></name>
<name><surname>Straatsma</surname><given-names>T.P.</given-names></name>
</person-group><article-title>The missing term in effective pair potentials</article-title><source>J. Phys. Chem.</source><year>1987</year><volume>91</volume><fpage>6269</fpage><lpage>6271</lpage><pub-id pub-id-type="doi">10.1021/j100308a038</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-18-00270"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciftci</surname><given-names>H.</given-names></name>
<name><surname>Sever</surname><given-names>B.</given-names></name>
<name><surname>Ayan</surname><given-names>E.</given-names></name>
<name><surname>Can</surname><given-names>M.</given-names></name>
<name><surname>DeMirci</surname><given-names>H.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>TuYuN</surname><given-names>A.F.</given-names></name>
<name><surname>Tateishi</surname><given-names>H.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
</person-group><article-title>Identification of New L-Heptanoylphosphatidyl Inositol Pentakisphosphate Derivatives Targeting the Interaction with HIV-1 Gag by Molecular Modelling Studies</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>1255</elocation-id><pub-id pub-id-type="doi">10.3390/ph15101255</pub-id><pub-id pub-id-type="pmid">36297367</pub-id>
</element-citation></ref><ref id="B76-pharmaceuticals-18-00270"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciftci</surname><given-names>H.</given-names></name>
<name><surname>Sever</surname><given-names>B.</given-names></name>
<name><surname>Bayrak</surname><given-names>N.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>M.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>H.</given-names></name>
<name><surname>Tateishi</surname><given-names>H.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>TuYuN</surname><given-names>A.F.</given-names></name>
</person-group><article-title>In Vitro Cytotoxicity Evaluation of Plastoquinone Analogues Against Colorectal and Breast Cancers Along with In Silico Insights</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>1266</elocation-id><pub-id pub-id-type="doi">10.3390/ph15101266</pub-id><pub-id pub-id-type="pmid">36297378</pub-id>
</element-citation></ref><ref id="B77-pharmaceuticals-18-00270"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciftci</surname><given-names>H.</given-names></name>
<name><surname>Sever</surname><given-names>B.</given-names></name>
<name><surname>Kaya</surname><given-names>N.</given-names></name>
<name><surname>Bayrak</surname><given-names>N.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>M.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>H.</given-names></name>
<name><surname>Tateishi</surname><given-names>H.</given-names></name>
<name><surname>Otsuka</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
<name><surname>TuYuN</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Studies on 1,4-Quinone Derivatives Exhibiting Anti-Leukemic Activity Along with Anti-Colorectal and Anti-Breast Cancer Effects</article-title><source>Molecules</source><year>2022</year><volume>28</volume><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28010077</pub-id><pub-id pub-id-type="pmid">36615273</pub-id>
</element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Table</title><fig position="float" id="pharmaceuticals-18-00270-f001"><label>Figure 1</label><caption><p>Pyrimidine-bearing EGFR inhibitors.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f002"><label>Figure 2</label><caption><p>Chalcone derivatives, compounds <bold>7e</bold> [<xref rid="B45-pharmaceuticals-18-00270" ref-type="bibr">45</xref>], <bold>11</bold> [<xref rid="B46-pharmaceuticals-18-00270" ref-type="bibr">46</xref>], and <bold>7b</bold> [<xref rid="B47-pharmaceuticals-18-00270" ref-type="bibr">47</xref>], with EGFR inhibitory activity against NSCLC and/or breast cancer cells.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f003"><label>Figure 3</label><caption><p>Thiazolyl&#x02013;pyrazolines (compounds <bold>11</bold> [<xref rid="B50-pharmaceuticals-18-00270" ref-type="bibr">50</xref>], <bold>6c</bold> [<xref rid="B51-pharmaceuticals-18-00270" ref-type="bibr">51</xref>], <bold>3f</bold> [<xref rid="B52-pharmaceuticals-18-00270" ref-type="bibr">52</xref>], <bold>10b</bold> [<xref rid="B53-pharmaceuticals-18-00270" ref-type="bibr">53</xref>], <bold>10d</bold> [<xref rid="B53-pharmaceuticals-18-00270" ref-type="bibr">53</xref>], <bold>6e</bold> [<xref rid="B54-pharmaceuticals-18-00270" ref-type="bibr">54</xref>], and <bold>BTT-5</bold> [<xref rid="B55-pharmaceuticals-18-00270" ref-type="bibr">55</xref>]) with EGFR inhibitory activity against NSCLC and/or breast cancer cells.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-sch001"><object-id pub-id-type="pii">pharmaceuticals-18-00270-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Reagents and conditions: (<bold>i</bold>) 2-(4-Chlorophenyl)pyrimidine-5-carbaldehyde, NaOH, ethanol, rt, 24 h. (<bold>ii</bold>) Thiosemicarbazide, NaOH, ethanol, reflux, 8&#x02013;12 h. (<bold>iii</bold>) 2-Bromo-1-arylethanone, ethanol, reflux, 2&#x02013;6 h.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-sch001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f004"><label>Figure 4</label><caption><p>NMR diagram for <bold>B-4</bold>, <bold>B-9</bold>, and <bold>BH1-7</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f005"><label>Figure 5</label><caption><p>Cytotoxicity values of <bold>B-4</bold>, <bold>B-9</bold>, and <bold>BH1-7</bold> against A549 (<bold>a</bold>) and MCF-7 (<bold>b</bold>) cells at 100 &#x000b5;M concentration compared to lapatinib.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f006"><label>Figure 6</label><caption><p>Changes in A549 (<bold>a</bold>) and MCF-7 (<bold>b</bold>) cells after control and <bold>B-4</bold> treatment for 24 h.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g006" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f007"><label>Figure 7</label><caption><p>EGFR inhibition of <bold>B-4</bold> at 10 &#x003bc;M and 1 &#x003bc;M concentrations.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g007" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f008"><label>Figure 8</label><caption><p>The calculated root mean square deviations of the EGFR (<bold>top</bold>) and the <bold>B-4</bold> (<bold>bottom</bold>) during 300 ns of MD run.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g008" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f009"><label>Figure 9</label><caption><p>Frequency of the contacts generated after 300 ns of the MD simulation. Only contacts that are observed at least for 40% of the simulation time are shown.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g009" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f010"><label>Figure 10</label><caption><p>The interaction map for <bold>B-4</bold>/EGFR complex extracted from the most populated cluster during MD run.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g010" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f011"><label>Figure 11</label><caption><p>The chemical structure and bioavailability radar of <bold>B-4</bold> from the SwissADME webtool.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g011" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00270-f012"><label>Figure 12</label><caption><p>The chemical structure and bioavailability radar of <bold>B-4</bold> from the SwissADME webtool. BBB: Blood&#x02013;brain barrier; HIA: human intestinal absorption; PGP: P-glycoprotein.</p></caption><graphic xlink:href="pharmaceuticals-18-00270-g012" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00270-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00270-t001_Table 1</object-id><label>Table 1</label><caption><p>The IC<sub>50</sub> values of <bold>B-4</bold> against A549, MCF-7, Jurkat cells, and PBMCs in comparison to lapatinib.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Compound</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IC<sub>50</sub> Values (&#x003bc;M)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">SI *</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 Cells</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCF-7 Cells</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jurkat Cells</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBMCs</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>B</bold>
<bold>-</bold>
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.49 &#x000b1; 2.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.70 &#x000b1; 1.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.50 &#x000b1; 0.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.89 &#x000b1; 10.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.21 &#x000b1; 3.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.71 &#x000b1; 1.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.43 &#x000b1; 0.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.71 &#x000b1; 2.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.89</td></tr></tbody></table><table-wrap-foot><fn><p>* Selectivity Index (SI) = IC<sub>50</sub> for PBMC/IC<sub>50</sub> for Jurkat cell line.</p></fn></table-wrap-foot></table-wrap></sec></back></article>